Immunomodulatory chimeric proteins
Chimeric CTLA4-IL 10 fusion proteins address stability and immunogenicity challenges, providing improved immunotherapy for autoimmune diseases by simultaneously binding to IL10R and CD80/CD86, achieving potent immunosuppression and anti-inflammation.
Patent Information
- Application Number
- PCT/IL2026/050386
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Designing and manufacturing bispecific proteins for immunotherapy, particularly for autoimmune diseases, is challenging due to issues like stability, complexity, and potential immunogenicity, with existing therapies showing limited efficacy and safety concerns.
Development of chimeric fusion proteins comprising Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) and Interleukin-10 (IL 10) polypeptides that covalently bind to both IL10R and CD80/CD86 receptors, offering improved immunosuppressive and anti-inflammatory properties.
The fusion proteins demonstrate potent immunosuppressive activity comparable to dexamethasone, with enhanced safety and efficacy in treating inflammatory and autoimmune disorders, including inflammatory bowel disease, by inhibiting pro-inflammatory cytokine secretion.
Smart Images

Figure IMGF000032_0001_TABLE 
Figure IMGF000037_0001_TABLE 
Figure IMGF000041_0001_TABLE
Abstract
Description
[0001] IMMUNOMODULATORY CHIMERIC PROTEINS FIELD OF THE INVENTION
[0002] The invention relates to the field of immunotherapy, in particular to novel chimeric proteins exhibiting an improved immunomodulatory activity.
[0003] BACKGROUND OF THE INVENTION
[0004] Bispecific proteins represent a frontier in therapeutic development for treating a range of diseases (Brinkmann et al. MAbs. 2017, 9: 182-212). These engineered proteins are designed to combine the functional elements of two or more distinct proteins, enabling them to simultaneously target multiple cellular components. The simultaneous binding to multiple receptors leads to improved therapeutic outcomes, for instance in cancer therapy, where bispecific antibodies bind to a cancer cell and a T cell, directing the immune system to target the tumor. Beyond oncology, bispecific proteins play a role in autoimmunity, infectious diseases, and metabolic disorders, showcasing their versatility (Brinkmann et al. 2017, ibid). Although it poses an attractive therapeutic approach, the design of bispecific protein is often challenging and associated with poor protein stability, manufacturing complexities, and potential immunogenicity (DiGiandomenico et al. Sci Transl Med. 2014, 6: 262ral55; Hober et al., Methods. 2019, 154: 143-152). Despite these hurdles, the clinical success of several chimeric and bispecific proteins has proven their potential to exhibit enhanced specificity and reduced off-target effects compared to single-target therapeutics. An important therapeutic field that could benefit from the development of bispecific proteins is autoimmune diseases (Zhao Q. BioDrugs. 2020, 34: 111-119), often resulting from misbalanced immune activating and suppressing responses. Among these, interleukin 10 (IL 10) and cytotoxic T lymphocyte-associated antigen-4 (CTLA4) are two proteins that play a significant role in immune regulation.
[0005] Interleukin 10 (IL 10) is an anti-inflammatory cytokine that down-regulates the expression of Thl cytokines, MHC class II and costimulatory molecules on macrophages. Its function is mediated by the interaction with the heterodimeric IL 10 receptor (IL10R1 and IL10R2). However, IL10 is known to also stimulate FcyR expression on the same cells, and has been shown to prolong B cell survival, induce B cell differentiation and enhance B cell proliferation and antibody production (Lalani et al. Ann Allergy Asthma Immunol. 1997,79: 469-483). Therefore, ILlO's complex interactions with diverse immune cell types and its role in balancing cytokine release mark it as an important protein in health and disease.
[0006] The importance and involvement of IL 10 in gut inflammation was demonstrated by IL10 knockout mice that developed chronic colitis (Rennick et al., Am J Physiol Gastrointest Liver Physiol. 2000;278(6): G829-G833). Loss of IL10 activity has been genetically linked to early onset IBD in humans and rodents (Glocker et al., N Engl J Med. 2009;361(21):2033-2045). In addition, defects in the IL10 receptor genes IL10RA and IL10RB and IL10 itself lead to early-onset enterocolitis involving hyperinflammatory immune responses in the intestine due to abrogated ILlO-induced signaling and therefore improper function of regulatory T cells. IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4+T cells in IBD patients.
[0007] Interestingly, clinical trials of IL10 as a treatment for inflammatory diseases showed that there were no significantly reduced remission rates or clinical improvements when compared to placebo (Buruiana et al. Syst Rev. 2010, CD005109; Herfarth et al., Gut. 2002, pp. 146-147; Saxena et al., Cytokine. 2015, 74: 27-34). A possible explanation for these results is that ILlO’s non-predictable immunostimulatory effects counterbalance its immunosuppressive properties.
[0008] Cytotoxic T-lymphocyte associated protein 4 (CTLA4), also known as CD152, is a membrane glycoprotein expressed by activated T cells and participates in the repression of T cell proliferation, cell cycle progression and cytokine production (Corse et al. J Immunol.
[0009] 2012, 189: 1123-1127). CTLA4 competes with CD28 for binding to CD80 / 86 located on antigen-presenting cells (APCs) and effectively inhibits T-cells activation mediated by the APCs and T cells interaction. This led to research of the CTLA4 pathway in the development of therapeutics in cancer and autoimmune diseases.
[0010] Indeed, Fc-fusion to the extracellular domain of CTLA4 has been developed and clinically approved as an immunosuppressant (e.g., belatacept and abatacept). For example, higher affinity CTLA4-Ig (belatacept) from BMS is currently approved for immune suppression in renal transplantation (Vincenti, NEJM 2016, 374:333-343), while abatacept has proved to be successful in alleviating infiltrative and autoimmune diseases in a subset of patients.CTLA4 haploinsufficiency or impaired ligand binding results in a complex syndrome presenting with features of both autoimmunity and immunodeficiency. Blumberg and colleagues identified a novel loss of function mutation in CTLA4, a surface molecule of regulatory T cells that directly suppresses effector T cell populations, in very early onset IBD (Zeissig et al., Gut. 2015;64(12): 1889-1897).
[0011] W02020 / 249003 relates to a protein comprising an antibody or antigen-binding fragment and an interleukin molecule operably linked to the antibody or antigen-binding fragment. The antibody or antigen-binding fragment comprises a heavy chain variable domain and a chain variable domain and specifically binds to an immune checkpoint protein, inter alia PD-1, PD-L1, B7.1 or B7.2, and the interleukin molecule may be inter alia IL- 10.
[0012] Pellerin et al. (2018, Front. Immunol. 9:881) disclose the construction of APVO210, a bispecific anti-CD86-IL-10 fusion protein (ADAPTIR™) that induces antigen- specific T regulatory type 1 cells. APV02010 showed improved activity compared to either IL-10 or an anti-CD86 antibody alone and had subsequently entered clinical trials. However, while showing a promising safety profile, further studies with APVO210 were discontinued, mainly due to anti-drug antibodies hampering its activity (Asif MH. Aptevo halts development of drug for autoimmune diseases, cuts annual expenses. 3 Oct 2019; ClinicalTrials. Gov. [7 Mar 2024] study NCT03768219).
[0013] In addition to immune-related adverse effects, approaches based on monoclonal antibodies (mAbs) have high manufacturing costs, and given their large molecular weight, cannot penetrate well into tissues. Bacterial expression systems such as Escherichia coli (E. colt) systems may be used to reduce production costs, however several disadvantages have been reported to be associated with these systems. For example, lack of post-translation modifications in these systems often leads to protein misfolding and accumulation of inclusion bodies.
[0014] Thus, despite the potential of bispecific proteins for providing enhanced specificity and reduced off-target effects (Brinkmann et al. 2017, ibid), designing and manufacturing these proteins remains challenging due to issues like stability, complexity and potential immunogenicity (Wang et al. Antibodies (Basel). 2019, 8; Cohen et al. MAbs. 2021, 13: 1944017; Zhou et al. J Immunother Cancer. 2022, 10).There remains a need for effective and safe therapeutic modalities for immunotherapy and for managing inflammatory and autoimmune disorders. In particular, providing improved compositions and methods for treating inflammatory bowel diseases and alleviating gastrointestinal inflammation would be highly advantageous.
[0015] SUMMARY OF THE INVENTION
[0016] The invention relates to the field of immunotherapy, in particular to novel chimeric proteins exhibiting advantageous immunomodulatory activities. More specifically, provided are chimeric bispecific proteins comprising Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) and Interleukin- 10 (IL 10) -derived polypeptides. According to embodiments of the invention, disclosed herein is the construction and production of fusion proteins that bind to both cognate receptors IL10R and CD80 / CD86, and exhibit advantageous properties providing improved immunotherapy.
[0017] The invention is based, in part, on experiments demonstrating the production and characterization of non-naturally occurring (recombinant bioengineered) polypeptides as unique therapeutic agents. The agents, constructed as fusion proteins comprising covalently linked IL10 and CTLA4 domains, were capable of selectively binding to CD80 and IL10R simultaneously. Further, the tested fusion proteins were determined to inhibit the secretion of pro-inflammatory cytokines during both homeostasis and inflammatory conditions. The observed immunosuppressor activity was as potent as that of dexamethasone, a potent antiinflammatory and immunosuppressive drug known as the gold-standard in management of autoimmune disorders. In addition, the fusion proteins possess better anti-inflammatory and immunosuppressive properties compared to each of the components alone.
[0018] Accordingly, provided in embodiments of the invention are chimeric proteins, nucleic acid constructs encoding them, pharmaceutical compositions comprising the chimeric proteins and / or constructs, and methods for their use and manufacture. The compositions and methods in accordance with embodiments of the invention overcome challenges associated with hitherto known therapies, including IL10 and CTLA4 monotherapies and antibody-based therapies, for example with respect to efficacy, safety and tolerability, and provide for high yield production in various expression systems.According to one aspect, the present invention provides a chimeric protein comprising a Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) polypeptide covalently linked by a linker to an Interleukin-10 (IL10) polypeptide.
[0019] In some embodiments, the CTLA4 polypeptide is derived from a human CTLA4 and comprises at least the ectodomain of the human CTLA4.
[0020] In some embodiments, the CTLA4 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 15 or an amino acid sequence having at least 95% sequence identity thereto.
[0021] In some embodiments, the CTLA4 polypeptide consists essentially of one or more CTLA4 ectodomains.
[0022] In some embodiments, the CTLA4 polypeptide consists essentially of a single CTLA4 ectodomain.
[0023] In some embodiments, the CTLA4 ectodomain comprises the amino acid sequence set forth as SEQ ID NO: 15 or an amino acid sequence having at least 95% sequence identity thereto.
[0024] In some embodiments, the IL10 polypeptide is derived from a human IL10.
[0025] In some embodiments, the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 17 or an amino acid sequence having at least 95% sequence identity thereto.
[0026] In some embodiments, the IL10 polypeptide comprises one or more amino acid substitutions relative to wild-type IL10.
[0027] In some embodiments, the wild-type IL10 has the amino acid sequence set forth as SEQ ID NO: 39, and wherein the IL10 polypeptide comprises one or more substitutions at positions selected from 17, 35, 39, 81, 86, 92, 111, 127, 130, and 153 of SEQ ID NO: 39.
[0028] In some embodiments, the one or more substitutions are independently selected from Glyl7Cys, Thr35Pro, Met39Lys, Glu81Gly, Asp86Glu, Asn92Asp, PhelllSer, Alal27Glu, Lysl30Met, and Tyrl53Cys.
[0029] In some embodiments, the IL10 polypeptide comprises a combination of substitutions selected from:
[0030] (a) Glyl7Cys and Asp86Glu;(b) Met39Lys;
[0031] (c) Thr35Pro;
[0032] (d) Asn92Asp, PhelllSer, Alal27Glu, and Lysl30Met; and
[0033] (e) Glu81Gly and Tyrl53Cys.
[0034] In some embodiments, the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 23-27.
[0035] In some embodiments, the IL10 polypeptide consists essentially of an IL10 monomer. In some embodiments, the IL10 polypeptide consists essentially of an IL10 dimer. In some embodiments, the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 38 or an amino acid sequence having at least 95% sequence identity thereto.
[0036] In some embodiments, the CTLA4 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15, and the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NO: 17, SEQ ID NOs: 23-27, and SEQ ID NO: 38.
[0037] In some embodiments, the linker is a peptide linker of 10-20 amino acids in length. In some embodiments, the linker is a flexible peptide linker.
[0038] In some embodiments, the linker is a Gly-Ser linker.
[0039] In some embodiments, the chimeric protein further comprises at least one protein tag selected from the group consisting of: an affinity tag, a solubility tag, an expression tag and combinations thereof.
[0040] In some embodiments, the chimeric protein is a chimeric protein precursor adapted for manufacture in a bacterial expression system.
[0041] In some embodiments, the chimeric protein further comprises an N-terminal glutathione S-transferase (GST) tag and a C-terminal histidine tag.
[0042] In some embodiments, the chimeric protein has the amino acid sequence as set forth in SEQ ID NO: 1.
[0043] In some embodiments, the chimeric protein is a chimeric protein precursor adapted for manufacture in a mammalian expression system.In some embodiments, the chimeric protein further comprises a human IgG Fc domain, a hemagglutinin (HA) tag and a histidine tag.
[0044] In some embodiments, the chimeric protein has the amino acid sequence as set forth in any one of SEQ ID NOs: 3-5.
[0045] In some embodiments, the chimeric protein is devoid of solubility tags and expression tags.
[0046] According to a further aspect, the present invention provides a nucleic acid construct encoding the chimeric protein of the present invention.
[0047] In some embodiments, the nucleic acid construct has a nucleic acid sequence selected from SEQ ID NOs: 2, 40-42.
[0048] According to another aspect, the present invention provides an expression vector comprising the construct of the present invention.
[0049] According to a further aspect, the present invention provides a host cell comprising the expression vector of the present invention.
[0050] According to yet another aspect, the present invention provides a pharmaceutical composition comprising the chimeric protein of the present invention or a nucleic acid construct encoding same, further comprising a pharmaceutically acceptable carrier, excipient or diluent.
[0051] In some embodiments, the pharmaceutical composition is for use as a medicament. In some embodiments, the pharmaceutical composition is for use in treating or preventing an inflammatory or autoimmune disorder.
[0052] In some embodiments, the disorder is an autoimmune disorder selected from the group consisting of: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), celiac disease and type I diabetes.
[0053] In some embodiments, the disorder is a chronic inflammatory disorder, a gastrointestinal inflammatory disorder or an allergic disorder.
[0054] In some embodiments, the pharmaceutical composition is for use in reducing side effects associated with administration of an IL10 and / or CTLA4 therapy.According to a further aspect, the present invention provides a method for immunomodulation, comprising contacting immune cells characterized by surface expression of IL10R and at least one of CD80 and CD86, with the pharmaceutical composition of the present invention.
[0055] In some embodiments, the contacting is performed in vivo.
[0056] In some embodiments, the contacting is performed ex vivo.
[0057] According to a further aspect, the present invention provides a method for treating or preventing an inflammatory or autoimmune disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of the present invention.
[0058] In some embodiments, the disorder is an autoimmune disorder selected from the group consisting of: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), celiac disease and type I diabetes.
[0059] In some embodiments, the disorder is a chronic inflammatory disorder, a gastrointestinal inflammatory disorder or an allergic disorder.
[0060] According to a further aspect, the present invention provides a method for reducing side effects associated with administration of an IL10 and / or CTLA4 therapy in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of the present invention.
[0061] Other objects, features and advantages of the present invention will become clear from the following description and drawings.
[0062] BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figures 1A-1C. CTLA4-IL10 expression. Fig. 1A - Illustration of the bispecific CTLA4-IL10 protein construct containing an N-terminus GST tag followed by CTLA4 ECD (ectodomain), a linker, IL10 and a Hisx6 tag. Fig. IB - SDS-PAGE of expression test at different temperatures. Lane M, marker; lanes 2-3, before IPTG, supernatant (sup) and pellet, respectively; lanes 4-9, induction at 37 °C, 25 °C and 15 °C, sup and pellet, respectively. Black arrow represents overexpressed GST-CTLA4-IL10-6xHis. Fig. 1C - AlphaFold-predicted models of CTLA4-IL10 with and without the N-terminal GST tag.Figures 2A-2B. SDS-PAGE analysis of expression, extraction from inclusion bodies and purification of GST-CTLA4-IL10-6xHis. Fig. 2A - Lane M, marker; Lanes 1-2: Lysis, sup and pellet, respectively; Lanes 3-4: Sonication, sup and pellet, respectively; Lanes 5-6: Denaturation, sup and pellet, respectively. Fig.2B - unfolded GST-CTLA4-IL10-6xHis was purified by Ni-NTA column under denaturating conditions. Lane M, marker. Lanes 1-4: Load, flow-through (FT), wash and elution, respectively. Dashed rectangle represents GST-CTLA4-IL10-6xHis.
[0064] Figures 3A-3E. SDS-PAGE (Fig. 3A) and western blot analysis (Figs. 3B-3E) of refolded GST-CTLA4-IL10-6xHis. Lane M, marker; Lane 1: refolded GST-CTLA4-IL10-6xHis. (Figs.3B-3E) - detection with αHis (3B), αGST (3C), αCTLA4 (3D) and αIL10 (3E). The expected molecular weight is 61 kDa.
[0065] Figures 4A-4D. ELISA results of binding between GST-CTLA4-IL10-6xHis to its cognate receptors. Figs. 4A, 4C - binding between chimera protein to CD80 and Fc-ILIOR, respectively. Figs. 4B, 4D - a negative control; GST binding to CD80 and Fc-ILIOR, respectively. Control: without (w / o) the addition of the receptor (dashed line), w / o coating with GST-tagged proteins (dot pattern) and buffer only (i.e. blank, white).
[0066] Figures 5A-5F. GST-CTLA4-IL10-6xHis retains dual receptor binding as demonstrated by sandwich ELISA and biolayer interferometry (BLI). Fig. 5A - Binding (OD450) of GST-CTLA4-IL10-6xHis (" CTLA-IL10", gray) or GST-CTLA4-6xHis (" CTLA4", black) on coated (right) or uncoated (left) wells. Fig. 5B - schematic illustration of the ELISA assay. Fig. 5C, 5D - Representative sensorgrams and kinetic fits, and steadystate binding analysis, respectively, for CTLA4-IL10 binding to immobilized IL-10R. Fig.
[0067] 5E, 5F - Representative sensorgrams and kinetic fits, and steady-state binding analysis, respectively, for CTLA4-IL10 binding to immobilized CD80. GST alone was tested as a negative-control analyte under the same conditions. Data were globally fitted to a 1: 1 binding model. Values represent mean ± SD from three independent experiments.
[0068] Figures 6A-6C. Expression and evaluation of Fc-CTLA4-linker-TEV-IL10-HA-HIS (protein vl). Fig. 6A - SDS-PAGE; Fig. 6B - CD80 binding; Fig. 6C - Fc-ILIOR binding.
[0069] Figures 7A-7C. Expression and evaluation of IL10-CTLA4-Fc-HA-HIS (protein v2).
[0070] Fig. 7A - SDS-PAGE; Fig. 7B - CD80 binding; Fig. 7C - Fc-ILIOR binding.Figures 8A-8G. Expression and evaluation of IL10x2-CTLA4-FC-HA-HIS (protein v3). Fig. 8A - SDS-PAGE; Fig. 8B - CD80 binding; Fig. 8C - Fc-ILIOR binding. Figs. 8D, 8E - AlphaFold models of the IL10x2-CTLA4 structure with and without the Fc domain, respectively. Fig. 8F - Representative sensorgrams and kinetic fits (left), and steady-state binding analysis (right) for binding to immobilized IL-10R. Fig. 8G - Representative sensorgrams and kinetic fits (left), and steady-state binding analysis (right) for binding to immobilized CD80. Data were globally fitted to a 1: 1 binding model. Values represent mean ± SD from three independent experiments.
[0071] Figure 9. Tumor necrosis factor alpha (TNFα) secretion from RAW 264.7 macrophages incubated with or without lipopolysaccharide (LPS) and different concentration of the fusion protein (vl). Dexamethasone (DEX A) and recombinant IE- 10 (R-IL10) were used as a control.
[0072] Figures 10A-10B. Effect of the CTLA4-IL10 fusion protein (v3) on IFNγ secretion of virus-specific T cells. Co-culture of VSTs with APCs loaded with 200 ng / ml (Fig. 10A) or 1 ng / ml (Fig. 10B) of the Hexon peptide library, and treated with IL10, CTLA4, or CTLA4-IL10 protein. Legend - No antigen (NC): VSTs that were not exposed to Hexon antigen; Activated cells (PC): VSTs that were exposed to the Hexon antigen with no addition of protein. IL10, CTLA4, or CTLA4-IL10: VSTs that were exposed to the Hexon antigen and the specific protein. Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA using GraphPad Prism (****, p < 0.0001).
[0073] Figure 11. Effect of CTLA4-IL10 chimeric protein (v3) on NF AT luciferase activity in a Raji -Jurkat assay. Raji-expressing CD80 were pre-incubated without and with the indicated proteins (10 pM) for 30 min and then co-cultured with Jurkat PD-1 luciferase reporter cells. After 4.5 h, NF AT activity was measured. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA.
[0074] Figure 12. Effect of wild-type IL10 and IL10 variants on LPS- stimulated mouse macrophage cells (RAW 264.7). NC - negative control (PBS + 0.1% BSA + 5pM sodium phosphate). PC - positive control (25pg / mL Dexamethasone). Inflammation is represented by TNF-a concentration. Mouse r-ILlO - commercial recombinant IL10 from mouse, human r-ILlO - commercial recombinant IL10 from human. I-IL-10 – variant IL-10. Bars represent mean values ± SD of 3. Ordinary one-way ANOVA, ***p<0.0005 ****p<0.0001 vs. LPS.DETAILED DESCRIPTION OF THE INVENTION
[0075] The invention in embodiments thereof relates to novel bispecific immunomodulatory proteins, comprising Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) and Interleukin- 10 (IL 10) -derived polypeptides. According to embodiments of the invention, disclosed herein is the construction and production of fusion proteins that bind to both cognate receptors IL10R and CD80 / CD86, and exhibit advantageous properties providing for improved immunotherapy.
[0076] In one aspect, the invention relates to a chimeric protein, comprising a CTLA4 polypeptide covalently linked to an IL10 polypeptide.
[0077] The term “chimeric protein” is used herein interchangeably with “fusion protein” and refers to a single protein entity comprising at least two protein, polypeptide, or peptide components that are not naturally contiguous, wherein the components are covalently joined directly or indirectly via a linker to form a unified construct. A fusion protein is typically produced by joining at least two polynucleotide sequences that originally encode separate proteins, polypeptides, or peptides, such that translation of the joined coding sequences yields a single polypeptide chain comprising the respective components. Alternatively, a fusion protein may be produced by post translational covalent conjugation of protein, polypeptide, or peptide components that are synthesized or expressed separately, wherein the components are joined via one or more linkers, tags, or recognition motifs that facilitate chemical or enzymatic ligation. A non-limiting example of post translational fusion includes, sortase-mediated ligation, as described in more detail below.
[0078] " Cytotoxic T-Lymphocyte Associated Protein 4" (" CTLA4"), also known as CD152, refers to the protein which in humans is encoded by the CTLA4 gene (NCBI Gene ID 1493) and its full-length amino acid sequence is provided in UniProt accession no. P16410. It is a cell-surface immune regulatory protein belonging to the immunoglobulin (Ig) superfamily and functions as a critical inhibitory immune checkpoint receptor in adaptive immunity. CTLA4 is primarily expressed on activated T lymphocytes and constitutively expressed on regulatory T cells (Tregs), where it negatively regulates T-cell activation and proliferation. CTLA4 exerts its inhibitory activity by binding the B7 family ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells with substantially higher affinity and avidity than the co stimulatory receptor CD28, thereby limiting CD28 -mediated stimulatory signaling and dampening T-cell responses. The full-length protein includes, from the N-terminus to theC-terminus, a signal peptide, an extracellular immunoglobulin V-type (IgV) domain (also termed herein "ectodomain") that is responsible for the binding to CD80 / CD86 and also mediates CTLA4 homodimerization via disulfide bonding, a transmembrane domain and a cytoplasmic domain (cytoplasmic tail).
[0079] The term " CTLA4 polypeptide" as used herein refers to a protein moiety within the fusion protein that is derived from CTLA4, which comprises at least the ectodomain of CTLA4.
[0080] In one embodiment, the CTLA4 polypeptide comprises at least one recombinant human CTLA4 (rhCTLA4) polypeptide. In another embodiment, the CTLA4 polypeptide consists essentially of at least one recombinant human CTLA4 (rhCTLA4) polypeptide. In another embodiment, the CTLA4 polypeptide comprises at least the CTLA4 extracellular V domain (e.g. an isolated rhCTLA4 ectodomain). In another embodiment, the CTLA4 polypeptide consists essentially of the CTLA4 extracellular V domain (e.g. an isolated rhCTLA4 ectodomain). In another embodiment the CTLA4 polypeptide comprises a plurality of CTLA4 ectodomains, typically located one after the other and separated by a linker. In another embodiment, the CTLA4 polypeptide consists essentially of a plurality of CTLA4 ectodomains. According to these embodiments, the number of CTLA4 ectodomains is preferably an even number (most preferably 2 or 4) which, without being bound by any particular theory or mechanism of action, facilitates intra-dimerization and a more homogenous protein product. Thus, in some embodiments, the CTL4 polypeptide comprises one or more CTLA4 ectodomains, preferably one, two or four CTL4 ectodomains. In additional embodiments, the CTLA4 polypeptide consists essentially of one or more CTLA4 ectodomains, preferably one, two or four CTL4 ectodomains. Each possibility represents a separate embodiment of the present invention. In yet other embodiments, the CTLA4 polypeptide further comprises additional CTLA4 domains such as the transmembrane domain and the cytoplasmic domain. In another embodiment the CTLA4 is a CTLA4 variant or isoform, such as a soluble human CTLA4 isoform (splice variant). In another embodiment the CTLA4 polypeptide comprises a rhCTLA4 monomer, meaning that the chimeric protein contains a single copy of the rhCTLA4. In another embodiment, the CTLA4 polypeptide consists essentially of a rhCTLA4 monomer. In another embodiment the CTLA4 polypeptide comprises a rhCTLA4 dimer, meaning that the chimeric protein contains two copies of the rhCTLA4, typically located one after the other. In anotherembodiment, the CTLA4 polypeptide consists essentially of a rhCTLA4 dimer. In another embodiment the CTLA4 polypeptide comprises a plurality of rhCTLA4 monomers or dimers. In another embodiment, the CTLA4 polypeptide consists essentially of a plurality of rhCTLA4 monomers or dimers. Each possibility represents a separate embodiment of the invention.
[0081] In some embodiments, the CTLA4 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 15, which corresponds to the ectodomain of human CTLA4, as follows:
[0082] HVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNEL TFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPE PCP (a CTLA4 polypeptide, SEQ ID NO: 15).
[0083] In some embodiments, the amino acid sequence of the CTLA4 polypeptide consists essentially of SEQ ID NO: 15. In additional embodiments, the amino acid sequence of the CTLA4 polypeptide is as set forth in SEQ ID NO: 15.
[0084] Also encompassed by the present invention are CTLA4 polypeptides with at least 90%, at least 95%, or at least 99% sequence identity to SEQ ID NO: 15, including each value within the range, each possibility representing a separate embodiment of the present invention.
[0085] " Interleukin- 10" (" IL10") refers to the protein which in humans is encoded by the IL10 gene (NCBI Gene ID: 3586) and its full-length amino acid sequence is provided in UniProt accession no. P22301. It is a secreted cytokine that functions as a major anti-inflammatory and immunoregulatory mediator in the human immune system. IL- 10 is produced primarily by monocytes, macrophages, dendritic cells, regulatory T cells, and certain lymphocyte subsets. Its biological activity includes suppression of inflammatory responses by inhibiting the synthesis and release of pro-inflammatory cytokines (including IFN-y, TNF-a, IL-1, IL-6, and IL- 12), down-regulation of MHC class II and co-stimulatory molecule expression on antigen-presenting cells, and promotion of B-cell survival, proliferation, and antibody production. IL- 10 signals through a heterotetrameric receptor complex comprising IL- 10 receptor alpha (IL 1 ORA) and IL- 10 receptor beta (IL 1 ORB). The full-length protein includes an N-terminal a signal peptide that is cleaved during intracellular processing to generate the mature, secreted cytokine.The term " IL10 polypeptide" as used herein refers to a protein moiety within the fusion protein that is derived from IL 10, which preferably comprises the mature form of IL 10 without the signal peptide. In another embodiment, the IL 10 polypeptide comprises at least one recombinant human IL10 (rhILlO) polypeptide. In another embodiment, the IL10 polypeptide consists essentially of a recombinant human IL10 (rhILlO) polypeptide. In another embodiment the IL 10 polypeptide comprises a rhILlO monomer, meaning that the chimeric protein contains a single copy of IL 10. In another embodiment, the IL 10 polypeptide consists essentially of a rhILlO monomer. In other embodiments, the chimeric protein may include multiple copies of IL 10, typically located one after the other and separated by a linker. According to these embodiments, the number of IL10 copies is preferably an even number (most preferably 2 or 4) which, without being bound by any particular theory or mechanism of action, facilitates intra-dimerization and a more homogenous protein product. Thus, in some embodiments, the IL10 polypeptide comprises one or more IL 10 monomers, preferably one, two or four IL 10 monomers. In additional embodiments, the IL10 polypeptide consists essentially of one or more IL10 monomers, preferably one, two or four IL10 monomers. Each possibility represents a separate embodiment of the present invention. In another embodiment, the IL 10 polypeptide advantageously comprises a rhILlO dimer, meaning that the chimeric protein contains two copies of the IL10, typically located one after the other. In another embodiments, the IL10 polypeptide consists essentially of a rhILlO dimer. In another embodiment, the IL10 polypeptide comprises a plurality of rhILlO monomers or dimers. In another embodiment, the IL10 polypeptide consists essentially of a plurality of rhILlO monomers or dimers. In another embodiment, the IL 10 polypeptide comprises at least the receptor-binding portion of IL 10. In another embodiment, the IL 10 is an IL 10 variant or isoform.
[0086] In some embodiments, the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 17, as follows:
[0087] PGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKG YLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKS KAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGS (an IL10 polypeptide, SEQ ID NO: 17)In some embodiments, the amino acid sequence of the IL10 polypeptide consists essentially of SEQ ID NO: 17. In additional embodiments, the amino acid sequence of the IL10 polypeptide is as set forth in SEQ ID NO: 17.
[0088] In some embodiments, the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 39, which corresponds to the natural mature form of IL10 after cleavage of its signal peptide. This sequence is identical to SEQ ID NO: 17 with the addition of a serine (S) at the N-terminus. In some embodiments, the amino acid sequence of the IL10 polypeptide consists essentially of SEQ ID NO: 39. In additional embodiments, the amino acid sequence of the IL10 polypeptide is as set forth in SEQ ID NO: 39.
[0089] In some embodiments, the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 23-27, which correspond to IL10 variants comprising one or more substitutions compared to wild-type IL10 as set forth in SEQ ID NO: 39. Each possibility representing a separate embodiment of the present invention.
[0090] In some embodiments, the amino acid sequence of the IL10 polypeptide consists essentially of an amino acid sequence selected from SEQ ID NOs: 23-27. In additional embodiments, the amino acid sequence of the IL10 polypeptide is selected from SEQ ID NOs: 23-27. Each possibility representing a separate embodiment of the present invention.
[0091] In some embodiments, the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 38, which includes two copies of IL10 (an IL10 dimer) separated by a linker.
[0092] In some embodiments, the amino acid sequence of the IL10 polypeptide consists essentially of SEQ ID NO: 38. In additional embodiments, the amino acid sequence of the IL10 polypeptide is as set forth in SEQ ID NO: 38.
[0093] In some embodiments, the amino acid sequence of the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NO: 17, SEQ ID NOs: 23-27, SEQ ID NO: 38 and SEQ ID NO: 39.
[0094] In some embodiments, the amino acid sequence of the IL10 polypeptide consists essentially of an amino acid sequence selected from SEQ ID NO: 17, SEQ ID NOs: 23-27, SEQ ID NO: 38 and SEQ ID NO: 39.In additional embodiments, the amino acid sequence of the IL10 polypeptide is selected from SEQ ID NO: 17, SEQ ID NOs: 23-27, SEQ ID NO: 38 and SEQ ID NO: 39.
[0095] Also encompassed by the present invention are IL 10 polypeptides with at least 90%, at least 95%, or at least 99% sequence identity to the aforementioned sequences, including each value within the range, each possibility representing a separate embodiment of the present invention.
[0096] In another embodiment the CTLA4 polypeptide is N-terminal to the IL 10 polypeptide. In another embodiment the CTLA4 polypeptide is C-terminal to the IL 10 polypeptide. In another embodiment the chimeric protein is a fusion protein. Typically, components of the protein are covalently linked by a linker, typically a peptide linker (for example, between the CTLA4 polypeptide and the IL10 polypeptide, or between two IL10 or CTLA4 monomers).
[0097] The terms “peptide” "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues linked by peptide bonds. The terms apply to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residues are an artificial chemical analog of a corresponding naturally occurring amino acid. The term “amino acid” is as known in the art and refers to compounds which have an amino group and a carboxylic acid group, for example in a 1,2- 1,3-, or 1,4-substitution pattern on a carbon backbone. The term encompasses the 20 natural amino acids found in proteins (which are L-amino acids except for glycine) and also non-natural amino acids such as the corresponding D-amino acids.
[0098] The polypeptides described herein may be chemically modified. The term "chemically modified" refers to an amino acid that is modified either by natural processes, or by chemical modification techniques which are well known in the art. Among the numerous known modifications, typical, but not exclusive examples include: acetylation, acylation, amidation, ADP-ribosylation, glycosylation, glycosaminoglycanation, GPI anchor formation, covalent attachment of a lipid or lipid derivative, methylation, myristlyation, pegylation, prenylation, phosphorylation, ubiqutination, or any similar process.
[0099] The term “peptide linker” refers to a peptide linking two different domains / moieties within the fusion protein.The term “flexible linker” as used herein refers to a peptide having an amino acid sequence which allows conformational flexibility of the peptides or proteins attached thereto. Examples include Gly-Ser linkers, poly-glycine linkers, and glycine-rich linkers. Specific examples include:
[0100] (GGS)n, (GS)n, (G)n, (GSG)n, (GGGGS)n, wherein n is an integer between 1-10, or between 2-10, or between 2-7, or between 2-5, including each integer value within the ranges. Each possibility represents a separate embodiment of the present invention; and (GmS)n linker wherein m is an integer from 1 to 5 (e.g., 1, 2, 3, 4, or 5) and n is an integer from 1 to 7 (e.g., 1, 2, 3, 4, 5, 6, or 7). Each possibility representing a separate embodiment of the present invention.
[0101] The length of a linker according to the present invention is in the range of 2-50 amino acids, for example 2-40 amino acids, 2-30 amino acids, for example, 3-30, 3-25, 3-20, 3-15, 5-30, 5-25, 5-20, 5-15, 10-30, 10-25, 10-20, 10-15 amino acids, including each integer value within the range, each possibility representing a separate embodiment of the present invention.
[0102] In some embodiments, the peptide linker comprises a plurality of contiguous amino acid residues selected from the group consisting of glycine, serine and / or alanine. In another embodiment the linker comprises a plurality of contiguous glycine and / or serine residues. In various embodiments, the linker may be at least 2 and more typically 4-30 amino acids in length (e.g. 2-30, 4-24, 4-8, 5-10, 6-18 or 2-6 amino acids in length). In another embodiment the linker is a flexible linker (e.g. a glycine- serine linker (Gn1S)n2or an oligo-glycine linker). In another embodiment the linker is a rigid linker (e.g. comprising the helix-forming motif (EAAAK)n, SEQ ID NO: 9). In another embodiment the linker is a glycine-serine linker (e.g. comprising 1-5 repeats of the core sequence GGGS or GGGGSS, SEQ ID NOs: 6 and 7, respectively). In a particular embodiment the glycine-serine linker is as set forth in SEQ ID NO: 8, as follows: GGGGS SGGGGS S. In various other embodiments, the use of other suitable linkers is contemplated, e.g. those disclosed in Chen et al., Adv Drug Deliv Rev. 2013, Oct;65(10): 1357-69, incorporated herein by reference.
[0103] In another embodiment, individual components of the chimeric protein (e.g. the IL10 polypeptide and the CTLA4 polypeptide) may be synthesized separately with linkers facilitating post-translational (e.g. chemical or enzymatic) conjugation, including, but notlimited to sortase recognition motifs. For example, the recognition motif (LPXTG, SEQ ID NO: 10) may be added to the C-terminus of a protein of interest while an oligo-glycine motif is added to the N-terminus of the second protein to be ligated. Upon addition of sortase to the protein mixture, the two peptides are covalently linked through a native peptide bond. Other examples include e.g. motifs compatible with Split Intein-Mediated Protein Ligation (SIMPL) and SpyCatcher-SpyTag technologies.
[0104] In another embodiment the linker is non-cleavable. In yet another embodiment the linker is cleavable. For example, linkers to be used in connection with the chimeric protein (e.g. flanking either or both ends of a protein tag as detailed below) may comprise a protease cleavage site. In another embodiment the chimeric protein further comprises at least one protease cleavage site. In another embodiment the protease cleavage site is selected from the group consisting of: a human rhinovirus 3C protease (HRV 3C) cleavage site, a tobacco etch virus (TEV) cleavage site, a Thrombin site and a FactorXa site. In another embodiment the chimeric protein comprises a HRV 3C site (e.g. between the GST and CTLA4 polypeptides) and a TEV cleavage site (e.g. between the CTLA4 and IL10 polypeptides). In some embodiments, the HRV 3C cleavage site has the sequence LEVLFQGP (SEQ ID NO: 11). In another embodiment the TEV cleavage site has a linear epitope of the general form E-X-X-Y-X-Q-(G / S), e.g. EDLYFQS or ENLYFQG (SEQ ID NOs: 12 and 13, respectively).
[0105] The present invention encompasses analogs of the peptides / proteins / polypeptides disclosed herein. The term “analog” as used herein denotes a peptide or protein or polypeptide having at least 85%, at least 90%, at least 95%, or at least 99% identity of its amino acid sequence to a given reference sequence, including each value within the range, each possibility representing a separate embodiment of the present invention.
[0106] An analog comprises an altered sequence by amino acid substitutions, additions, deletions, or chemical modifications. In some embodiments, by amino acid substitutions it is meant that functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent alteration. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polarneutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such substitutions are known as conservative substitutions. Additionally, a non-conservative substitution may be made, as long as the activity of the original protein / peptide / polypeptide is not negatively affected. An analog maintains at least 80%, 85%, 90%, 95%, or preferably 100% of the biological activity of the reference peptide or protein or polypeptide, as determined by in vitro or in vivo tests known in the art (see, for example, the Examples herein below). Analogs are included in the invention as long as they remain pharmaceutically acceptable, i.e., they do not destroy the activity of the protein and do not confer toxic properties on compositions containing it and have comparable or improved activity as an unmodified protein. The term “derivative” may be used interchangeably with “analog”.
[0107] Percent (%) sequence identity with respect to a reference sequence is the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known, for instance, using publicly available computer software such as BLAST, BLAST-20 2, ALIGN or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences can be determined, including algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0108] With respect to polynucleotides, it is understood by a person skilled in the art that several codons may be used to encode a given amino acid, and thus a polynucleotide sequence encoding a protein according to the present invention may differ from those presented herein but still encodes the same protein and is therefore encompassed by the present invention. It is also understood that a polynucleotide sequence to be included in an expression construct may be optimized for production in a certain cell of interest. Such codon-optimized sequences are further included within the scope of the present invention.
[0109] The polynucleotides sequences provided herein are provided as DNA sequences. It is to be understood that if an RNA sequence is contemplated, T is replaced with U.In another embodiment the chimeric protein further comprises at least one protein tag. In various embodiments the at least one protein tag is selected from the group consisting of an affinity tag, a solubility tag, an expression tag and combinations thereof. In another embodiment the protein tag is an affinity tag. In another embodiment the at least one protein tag is selected from the group consisting of: a glutathione S-transferase (GST) tag, a histidine tag and a hemagglutinin (HA) tag. In another embodiment (for example, for the production of a fusion protein in a bacterial expression system), the chimeric protein comprises a GST tag and a histidine tag. In a particular embodiment the chimeric protein comprises an N-terminal GST tag. In a particular embodiment the chimeric protein comprises a C-terminal histidine tag. In another embodiment the histidine tag is a 6xHis tag (HHHHHH, SEQ ID NO: 14). In other embodiments, the use of other protein tags, including, but not limited to solubility and / or expression tags such as Maltose binding protein (MBP) and A streptococcal protein-G B 1 domain (GB 1) tag, is contemplated, e.g. to support purification and / or enhance the solubility of the recombinant protein precursor (in particular in bacterial expression systems). In another embodiment for example, for the production of a fusion protein in a mammalian expression system) the chimeric protein comprises a HA tag and a histidine tag. In yet other embodiments (for example, in the mature chimeric protein, formulated for administration to human patients) the chimeric protein is devoid of solubility tags and expression tags. In another embodiment, the chimeric protein for administration is devoid of protein tags.
[0110] In another embodiment the chimeric protein may further comprise or be linked additional components such as a serum half-life-elongating moiety. For example, chimeric proteins of the invention may be chemically linked to a polyethyleneglycole (PEG) moiety or fused or linked to an IgG Fc domain (Fc). In particular, the use of Fc tags may be contemplated in the construction of fusion proteins to be expressed in mammalian systems. In yet another embodiment, said chimeric protein is a fusion protein consisting essentially of specific constructs as disclosed and exemplified herein.
[0111] In another embodiment, the chimeric protein is capable of selectively binding to a CTLA4 receptor and to an IL10 receptor. In another embodiment the CTLA4 receptor is human CD80 and / or CD86. In another embodiment the IL10 receptor is human IL10R. In another embodiment, the chimeric protein is capable of binding simultaneously to human CD80 and human IL10R. In another embodiment the binding is in cis. In anotherembodiment the binding is in trans. In another embodiment the chimeric protein is capable of binding preferentially to a human target cell expressing both CD80 and IL10R (e.g. an antigen-presenting cell or a macrophage). In another embodiment the chimeric protein exhibits immunomodulatory (e.g. immunosuppressor) activity. In another embodiment the chimeric protein is capable of inhibiting cytokine (e.g. TNFα) secretion from said target cell expressing both CD80 and IL10R. Without wishing to be bound by a specific theory or mechanism of action, chimeric proteins of the invention may be capable of binding said target cell with high affinity and / or avidity while exhibiting superior tissue penetration compared to antibody-based therapies directed to CD80 and / or IL10R.
[0112] In a particular embodiment the chimeric protein is a precursor composed of (from N-to C-terminus): a GST tag, a HRV 3C cleavage site (e.g. LEVLFQGP, SEQ ID NO: 12), a CTLA4 polypeptide, a glycine- serine linker (e.g., GGGGSSGGGGSS, SEQ ID NO: 8), a TEV-protease cleavage site (e.g. EDLYFQS, SEQ ID NO: 12), an IL10 polypeptide, and a 6xHis-tag (HIS).
[0113] In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: CTLA4-linker-IL10. In other embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: IL10-linker-CTLA4.
[0114] In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: IL10x2-linker-CTLA4. In other embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: CTLA4-linker-IL10x2.
[0115] Optionally, in some embodiments, the chimeric protein further comprises at least one of: (i) one or more protein tags selected from an affinity tag, a solubility tag, and an expression tag; (ii) a secretion signal (also termed herein a signal peptide); and (iii) a serum half-life-elongating moiety. Each possibility and combination represents a separate embodiment of the present invention.
[0116] In addition, the chimeric protein may further include protease cleavage site(s) between the components.
[0117] In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: Fc-CTLA4-linker-IL10. In other embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: CTLA4-linker-IL10-Fc.In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: IL10-linker-CTLA4-Fc. In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: Fc-IL10-linker-CTLA4.
[0118] In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: IL10x2-linker-CTLA4-Fc. In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: Fc-IL10x2-linker-CTLA4.
[0119] In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: Fc-CTLA4-linker-IL10x2. In some embodiments, a chimeric protein according to the present invention comprises from N- to C-terminus: CTLA4-linker-IL10x2-Fc.
[0120] In some embodiments, a chimeric protein according to the present invention comprises the sequence set forth in SEQ ID NO: 34 (CTLA4-linker-IL10).
[0121] In some embodiments, a chimeric protein according to the present invention comprises the sequence set forth in SEQ ID NO: 35 (Fc-CTLA4-linker-IL10).
[0122] In some embodiments, a chimeric protein according to the present invention comprises the sequence set forth in SEQ ID NO: 36 (IL10-linker-CTLA4-Fc).
[0123] In some embodiments, a chimeric protein according to the present invention comprises the sequence set forth in SEQ ID NO: 37 (IL10x2-linker-CTLA4-Fc).
[0124] According to an exemplary embodiment, an advantageous chimeric protein in accordance with the invention has the amino acid sequence as set forth in SEQ ID NO: 1, as follows:
[0125] MSP ILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPY YIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFET LKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLV CFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGPLGSHVAQPA VVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICT GTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPGGGGSS GGGGSSSEDLYFQSSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNL LLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGSHHHH HH
[0126] (GST-CTLA4-IL10-6xHis, SEQ ID NO: 1).
[0127] In another embodiment said chimeric protein is encoded by a nucleic acid molecule having the nucleic acid sequence as set forth in SEQ ID NO: 2, as follows:
[0128] ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTT CTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGAT AAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATT GATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCAC AACATGTTGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTT TTGGATATTAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAA GTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCAT AAAACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTT GATGTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTT AAAAAACGTATTGAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATA GCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCG GATCTGGAAGTTCTGTTCCAGGGGCCCCTGGGATCGCATGTGGCTCAGCCTGCCGTGGTC CTGGCCAGCTCCCGGGGCATCGCCTCTTTCGTGTGCGAGTACGCCAGCCCTGGCAAGGCA ACCGAGGTGAGGGTGACAGTGCTGAGGCAGGCAGACAGCCAGGTGACCGAGGTGTGCGCA GCAACATATATGATGGGCAACGAGCTGACCTTTCTGGACGATTCCATCTGTACCGGCACA TCTAGCGGCAACCAAGTGAATCTGACCATCCAGGGCCTGAGAGCTATGGACACAGGCCTG TACATCTGTAAGGTGGAGCTGATGTATCCCCCTCCATACTATCTGGGCATCGGCAACGGC ACACAAATCTACGTGATCGATCCAGAGCCTTGCCCAGGAGGAGGAGGCTCCTCTGGAGGA GGAGGCTCCTCTTCTGAGGATCTGTACTTTCAGAGCAGCCCAGGCCAGGGCACCCAGAGC GAGAACAGCTGTACACACTTCCCCGGCAACCTGCCTAATATGCTGCGGGACCTGAGAGAT GCCTTTTCCAGGGTGAAGACCTTCTTTCAGATGAAGGACCAGCTGGATAACCTGCTGCTG AAGGAGTCCCTGCTGGAGGACTTCAAGGGCTACCTGGGCTGCCAGGCCCTGTCTGAGATG ATCCAGTTTTATCTGGAGGAAGTGATGCCACAGGCCGAGAATCAGGACCCCGACATCAAG GCCCACGTGAACTCTCTGGGCGAGAATCTGAAGACACTGAGGCTGAGGCTGCGGAGATGC CACCGGTTCCTGCCCTGTGAGAACAAGTCTAAGGCCGTGGAGCAGGTGAAGAACGCCTTT AATAAGCTGCAGGAGAAGGGCATCTATAAGGCCATGAGCGAGTTCGACATCTTCATCAATTACATTGAAGCCTACATGACTATGAAGATTAGAAACGGCAGCCACCATCACCATCACCAT TAA
[0129] (GST-CTLA4-IL10-6xHis construct, SEQ ID NO: 2).
[0130] In another particular embodiment the chimeric protein is a precursor composed of (from N- to C-terminus): an Fc domain, a CTLA4 polypeptide, a glycine- serine linker, a TEV-protease cleavage site, an IL 10 monomer, an HA tag and HIS.
[0131] According to an exemplary embodiment, an advantageous chimeric protein in accordance with the invention has the amino acid sequence as set forth in SEQ ID NO: 3, as follows:
[0132] MGWSCI ILFLVATATGVHSGPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLM I SLSP IVTCVVVDVSEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQD WMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDF MPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGL HNHHTTKSFSRTPGKHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTE VCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGI GNGTQIYVIDPEPCPGGGGSSGGGGSSSENLYFQGSPGQGTQSENSCTHFPGNLPNMLRD LRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDP DIKAHVNSLGENLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDI FINYIEAYMTMKIRNGSYPYDVPDYAHHHHHH (Fc-CTLA4-linker-TEV-IL10-HA-HIS, SEQ ID NO: 3).
[0133] In another particular embodiment the chimeric protein is a precursor composed of (from N- to C-terminus): an IL10 monomer, a glycine- serine linker, a TEV-protease cleavage site, a CTLA4 polypeptide, an Fc domain, an HA tag and HIS.
[0134] According to an exemplary embodiment, an advantageous chimeric protein in accordance with the invention has the amino acid sequence as set forth in SEQ ID NO: 4, as follows:
[0135] MGWSCI ILFLVATATGVHSGPSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTF FQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGEN LKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKI RNGGGGSSGGGGSSSENLYFQGHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQA DSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDGGGSRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDV LMI SLSP IVTCVVVDVSEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQ DWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDF MPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLH NHHTTKSFSRTPGKGSYPYDVPDYAHHHHHH (IL10-CTLA4-FC-HA-HIS, SEQ ID NO: 4).
[0136] In another particular embodiment the chimeric protein is a precursor composed of (from N- to C-terminus): an IL10 dimer, glycine- serine linker, a TEV-protease cleavage site, a CTLA4 polypeptide, an Fc domain, an HA tag and HIS.
[0137] According to an exemplary embodiment, an advantageous chimeric protein in accordance with the invention has the amino acid sequence as set forth in SEQ ID NO: 5, as follows:
[0138] MGWSCI ILFLVATATGVHSGPSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTF FQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGEN LKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKI RNGGGSGGGSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLP CENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGGGGSSGGGGSSSE NLYFQGHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGN ELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDP EPCPDSDGGGSRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDV SEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALP IQHQDWMSGKEFKCKVNNKD LPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTE LNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKGS YPYDVPDYAHHHHHH (IL10x2-CTLA4-FC-HA-HIS, SEQ ID NO: 5).
[0139] In some embodiments, there is provided herein a variant IL10 comprising one or more substitutions compared to wild-type IL10. In some embodiments, the variant IL10 comprises an amino acid sequence selected from SEQ ID NOs: 23-27. Each possibility represents a separate embodiment of the present invention.
[0140] In some embodiments, the variant IL10 further comprises at least one of: (i) one or more protein tags selected from an affinity tag, a solubility tag, and an expression tag; (ii) a secretion signal (also termed herein a signal peptide); and (iii) a serum half-life-elongatingmoiety. Each possibility and combination represents a separate embodiment of the present invention.
[0141] In some exemplary embodiments, the variant IL 10 comprises a His tag. In some embodiments, the variant IL10 comprises a sequence selected from SEQ ID NOs: 18-22. Each possibility represents a separate embodiment of the present invention. In some embodiments, the DNA encoding a His tag-containing IL10 variant is selected from the group consisting SEQ ID NOs: 29-33. Each possibility represents a separate embodiment of the present invention.
[0142] In another aspect, there is provided a nucleic acid construct encoding the chimeric protein (in particular, a fusion protein precursor as disclosed herein). In another embodiment there is provided a vector, particularly an expression vector, comprising the construct. The term “vector” encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer genetic material to cells. A vector can include, but is not limited to, a cloning vector and an expression vector. An "expression vector" is a nucleic acid construct designed for delivery of genetic material to a host cell, for expressing a protein of interest within the host cell.
[0143] In another embodiment the expression vector is compatible for use in a recombinant expression system. In another embodiment the expression vector is compatible for use in a bacterial expression system. In another embodiment the bacterial expression system is an E. coli system. In a particular embodiment the system is E. coli BL21. Such vectors typically comprise a bacterial origin of replication functional in E. coli, one or more selectable markers (e.g., antibiotic resistance genes), and regulatory elements enabling controlled transcription and translation in a bacterial host. By way of example, suitable regulatory elements include inducible or constitutive promoters recognized by E. coli RNA polymerase, such as T7, T5, lac, tac, or trc promoters, optionally in combination with operator sequences for regulated expression, ribosome binding sites optimized for E. coli, and transcriptional terminators. In certain embodiments, the expression vector further includes sequences encoding affinity tags or fusion partners to facilitate protein detection, purification, or stabilization. Non-limiting examples of such vectors include pGEX-6P-1, which enables expression of heterologous polypeptides as glutathione S-transferase (GST) fusion proteins under control of an inducible promoter, as well as pET-series vectors (e.g., pET-21, pET-28), which utilize a T7 promoter for high-level expression in T7 RNA polymerase-expressingstrains such as BL21(DE3). Additional exemplary vectors include pMAL vectors that produce maltose-binding protein (MBP) fusion constructs to enhance solubility.
[0144] In another embodiment the system is a mammalian system (e.g. CHO cells). Such mammalian expression vectors generally comprise regulatory elements functional in mammalian cells, including one or more strong constitutive or inducible promoters, enhancers, transcriptional termination and polyadenylation signals, and translation initiation sequences. Non-limiting examples of suitable mammalian expression vectors include pcDNA3 and related vectors (e.g., pcDNA3.1), which utilize promoters such as the cytomegalovirus (CMV) immediate-early promoter to drive high-level expression in CHO cells and include selectable markers for stable or transient expression.
[0145] In another embodiment, there is provided a host cell comprising the vector.
[0146] In another embodiment, there is provided a pharmaceutical composition comprising the chimeric protein, further comprising a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, there is provided a pharmaceutical composition comprising a nucleic acid construct encoding the chimeric protein, further comprising a pharmaceutically acceptable carrier, excipient or diluent. In a particular embodiment the pharmaceutical composition is formulated for injection (e.g. intravenously). In other embodiments, additional administration routes, including in particular routes for systemic administration as known in the art. For example, for oral administration, suitable formulations (in which the active ingredient is encapsulated or otherwise protected from gastric degradation, e.g. enteric coated dosage forms), or conjugation to agents facilitating transcytosis across the intestinal epithelium (e.g. a Chx exotoxin transcytosis domain) may be used.
[0147] Such pharmaceutical compositions are formulated to maintain the stability, bioactivity, and pharmacological effectiveness of the protein or nucleic acid and to enable safe and effective delivery by a desired route of administration. Non-limiting examples of suitable formulations include aqueous solutions, suspensions, emulsions, lyophilized preparations for reconstitution, and controlled-release formulations. Pharmaceutically acceptable carriers may include buffers, isotonicity agents, stabilizers, preservatives, antioxidants, surfactants, or solubilizing agents, as known in the art for protein-based therapeutics. The pharmaceutical compositions may be formulated for parenteral administration, includingintravenous, subcutaneous, intramuscular, or intraperitoneal delivery, as well as other routes as appropriate.
[0148] Non-limiting examples of pharmaceutically acceptable excipients for protein formulations include: buffers such as phosphate buffers, citrate buffers, acetate buffers, histidine, and Tris; stabilizers / protectants including sugars and polyols such as sucrose, trehalose, mannitol, sorbitol, and glycerol; tonicity agents such as sodium chloride, potassium chloride, dextrose, or mannitol; surfactants such as polysorbate 20, polysorbate 80, and poloxamers; and bulking agents (for lyophilized formulations) such as mannitol, glycine, or sucrose.
[0149] In another embodiment, the pharmaceutical composition is for use as a medicament. In some embodiments, the pharmaceutical composition is for use in treating or preventing an inflammatory or autoimmune disorder. In another embodiment the disorder is an autoimmune disorder. The terms "treatment" and “treating”, used herein interchangeably, are meant to include: (a) relieving the conditions and related diseases, i.e., causing regression of the conditions and diseases; (b) inhibiting the conditions and diseases, i.e., arresting its development (e.g., reducing the rate of conditions and diseases progression); and (c) relieving or reducing one or more symptoms of the conditions and diseases.
[0150] The term "therapeutically effective amount" of an active agent means an amount of the active agent effective to abate, alleviate, control, attenuate the progression, improve the prognosis, and / or treat related symptoms.
[0151] Determination of a therapeutically effective amount is within the capability of those skilled in the art, especially in light of the disclosure provided herein.
[0152] A subject to be treated according to the present invention is typically a human subject. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition.
[0153] For example, without limitation, the disorder may be inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), celiac disease and type I diabetes. In another embodiment the disorder is a chronic inflammatory disorder. In another embodiment the disorder is a gastrointestinal (GI) inflammatory disorder (e.g. IBD, colitis, ileocolitis, ileitis, gastroduodenal Crohn's disease, jejunoileitis, or Crohn's colitis). In a particular embodimentthe disorder is IBD (e.g. Crohn's disease or ulcerative colitis). In another embodiment the inflammatory is an allergic disorder (e.g. asthma or allergic rhinitis).
[0154] In another embodiment the pharmaceutical composition is for use in reducing side effects associated with administration of an IL10 and / or CTLA4 therapy. In another embodiment the pharmaceutical composition is for use in enhancing the efficacy of an IL10 and / or CTLA4 therapy.
[0155] Typically, a chimeric protein used as an active ingredient in a pharmaceutical composition as disclosed herein is a mature (processed) chimeric protein, which is advantageously devoid from solubility tags and expression tags. In addition, chimeric protein precursors as disclosed herein (which typically comprise such tags) may conveniently be used as reagents for research and diagnostic purposes.
[0156] In another aspect there is provided a method for immunomodulation, comprising contacting immune cells expressing at least one receptor selected from the group consisting of IL10R, CD80 and CD86 with a pharmaceutical composition as disclosed herein. In another embodiment the immune cells are characterized by surface expression of IL10R and at least one of CD80 and CD86. In another embodiment the immune cells express both IL10R and CD80. In another embodiment the contacting is performed in vivo. In another embodiment the contacting is performed ex vivo.
[0157] In another aspect there is provided am method for treating a disorder as disclosed herein in a subject in need thereof, comprising administering the pharmaceutical composition to the subject.
[0158] In other aspects, processes for producing chimeric proteins of the invention are contemplated. In one embodiment the process employs the use of a bacterial expression system (e.g. an E. coli system such as BL21). In another embodiment the process employs the use of a mammalian expression system. For example, suitable production processes in bacterial systems may include over-expression of the construct (e.g. using strong inducible promoters such as IPTG-induced promoters) to form a soluble protein or bacterial inclusion bodies. The inclusion bodies may conveniently be isolated using affinity chromatography (e.g. Ni column for constructs containing a histidine tag). The chimeric protein may then be extracted from the inclusion bodies by a process including solubilization, purification and refolding. For example, without limitation, the process may comprise solubilization ofinclusion bodies in the presence of suitable denaturation agents such as urea and / or guanidine hydrochloride, and gradual renaturation by stepwise dialysis in the presence of reduced concentrations of the denaturation agents. In another example, fusion proteins produced in mammalian systems may conveniently isolated using affinity chromatography in a substantially purified and soluble form, not requiring additional processing steps. Non- limitative examples of such manufacture processes are provided in the Examples section below.
[0159] The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention.
[0160] EXAMPLES
[0161] Materials and methods
[0162] Isolation of chimera protein from inclusion bodies and purification under denaturing condition
[0163] Purification of GST-CTLA4-IL10-6xHis was performed from the bacterial inclusion bodies at 4 °C unless otherwise mentioned. Pellet was resuspended in 0.1 g / mL lysis buffer [50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 10 mM EDTA, 5 mM dithiothreitol (DTT), 2% triton X-100 and protease inhibitor 1:500], sonicated (10x30 s at 40% amplitude for 10 min, Qsonica sonicator Q125) and centrifuged (20,000 xg for 20 min). Inclusion bodies were solubilized in 30 mL denaturation buffer [20 mM Tris-HCl (pH 8), 0.5 M NaCl and 6 M guanidine hydrochloride, pH 8] and stirred ON at room temperature (RT). Next, the clear suspension was filtered via 0.22 μm membrane and further purified on HisTrap FF 5 mL column (Cytiva) in an AKTA go purification system, using equilibration buffer [20 mM Tris-HCl (pH 8), 500 mM NaCl, 5 mM imidazole, 6 M guanidine hydrochloride, pH 8], wash buffer [20 mM Tris-HCl (pH 8), 500 mM NaCl, 20 mM imidazole, 6 M urea, pH 8) and elution buffer [20 mM Tris-HCl (pH 8), 500 mM NaCl, 6 M urea, pH 8]. Fractions containing GST-CTLA4-IL10-6xHis were dialyzed over-night while stirring against 2 L of refolding buffer [880 mM L-arginine free base, 55 mM Tris-HCl (pH 8), 10 mM NaCl, 0.88 mM KCl, 1 mM EDTA, 1 mM cystine and 5 mm cysteine, pH 8] and decreasing urea concentrations: 3 and 0 M. The folded protein was filtered via a 0.22 μm membrane and stored at -20 °C in a freezing buffer [880 mM L-arginine free base, 55 mM Tris-HCl (pH 8), 10 mM NaCl, 0.88 mM KCl, 1 mM EDTA, 1 mM cystine and 5 mm cysteine, pH 8] containing 20% glycerol.SDS-PAGE and Western blot
[0164] Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to identify the purity of the refolded fraction. SDS sample preparation included the addition of sample buffer composed of β-mercaptoethanol (BME) as a reducing reagent, 0.2 M tris-HCl, 8% (w / v) SDS, 6 mM bromophenol blue, 4.3 M glycerol. For western blot, 10 pL of purified protein were loaded onto 1 mm 10 wells SDS-PAGE gel, along with a molecular weight marker; the gel was then run for 80 min at 120 V and then electroblotted onto a polyvinylidene difluoride (PVDF) membrane. Post-transfer membrane was placed for 1 h at RT in a blocking buffer containing 5% skim milk in PBS-T 0.05 % (Tween 20 was added to IX PBS and 5% skim milk to a final concentration of 0.05%). The membrane was then incubated ON at 4 °C with appropriate primary antibody (Table 1) diluted in PBS-T 0.05% buffer. The next day, the membrane was washed with PBS-T 0.05% buffer and further incubated for 1 h at RT with the recommended dilution of conjugated secondary antibody (Table 1) in blocking buffer PBS-T 0.05%. Next, the membrane was washed and developed using 1 mL ECL (Merck) via ChemiDoc (BioRad) and analyzed.
[0165] ELISA binding assay
[0166] The ELISA assay was performed using a compatible PVC clear high bind ELISA microtiter 96-well plate (NEST). First, coating was made with GST-CTLA4-IL10-6xHis, diluted to 2 pg per well at a final volume of 100 pL. The plate was incubated ON at 4 °C, and afterward, it was washed 5 times with PBS-T 0.05%. 200 pL of blocking solution (5% skim milk in PBS-T 0.05%) was added and the plate was incubated for 5 h at RT to prevent non-specific binding. After incubation, the plate was washed 5 times with PBS-T 0.05% and 0.2 pg CD80 (His & AVI tag biotinylated, SinoBiological) or Fc-ILIOR (R& D systems, USA) was added to relevant wells at a final volume of 100 pL. Next, the plate was incubated at 4 °C ON. Following 5 washes with PBS-T 0.05%, blocking for 2 h and additional washes, 100 pL of Fc-HRP conjugated antibody or streptavidin-HRP (1 pL antibody diluted in 7 mL PBS) were added at a final volume of 100 pL to relevant wells and incubated at RT for 1 h. Washing steps were repeated, then 100 pL of TMB (SurModics) were added to each well and the plate was incubated at RT up to 1 h. After color development, 50 pL of 0.5 M H2SO4were added to each well to stop the enzymatic reaction. Plate absorbance was immediately measured using a plate reader (BioTek synergy H1) at 450 nm absorbance.Primary and secondary antibodies used for ELISA and Western blot experiments described herein are listed in Table 1 below.
[0167] Table 1. Primary and secondary antibodies used for ELISA and / or Western blot.
[0168]
[0169] Biolayer interferometry (BLI) affinity measurements using Octet96
[0170] Affinity measurements of the CTLA4-IL10-containing fusion proteins to CD80 and IL10R were performed using Octet® RED96 (Satorius Ltd). Measurements were at 25°C in PBS supplemented with 0.02% Tween-20 and 0.1% BSA to minimize non-specific binding. For binding measurements, 5 ng / mL of biotinylated human CD80 (BPS) or 2.5 ng / mL of biotinylated IL10R (Antibodies online) were immobilized onto streptavidin biosensors. Serial dilutions of the protein (ranging from 0.01μM to 2μM) were prepared in the same buffer and loaded for 500s to record the association phase, followed by dissociation for an additional 600s in buffer alone.
[0171] Example 1. Gene synthesis and plasmid construction for bacterial expression DNA sequences encoding the ectodomain (ECD) of human CTLA4 and IL10 (UniProt P16410 and P22301, respectively) were synthesized andcodon-optimized for E. coli expression (Genscript Inc.). The synthetic fusion gene was cloned together with a C-terminal histidine tag via Gibson assembly into pGEX-6P-1 containing an N-terminal GST tag. A linker composed of repetitions of glycine- serine was inserted for the separation of CTLA4 and IL 10. The synthetic gene further included an HRV-3C protease cleavage site between the GST tag and the CTLA4 domain, and a TEV cleavage site between the CTLA4 and IL10 domains.
[0172] The DNA sequence of the GST-CTLA4-IL10-6xHis is set forth in SEQ ID NO: 2 below:
[0173] ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTT TGGAATATCTTGAAGAAAAATATGAAGAGCATTTGTATGAGCGCGATGAAGGTGATAAATG GCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATTGATGGT GATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGT TGGGTGGTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATAT TAGATACGGTGTTTCGAGAATTGCATATAGTAAAGACTTTGAAACTCTCAAAGTTGATTTT CTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGTCATAAAACATATT TAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTT ATACATGGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATT GAAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGC AGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGAAGTTCT GTTCCAGGGGCCCCTGGGATCGCATGTGGCTCAGCCTGCCGTGGTCCTGGCCAGCTCCCGG GGCATCGCCTCTTTCGTGTGCGAGTACGCCAGCCCTGGCAAGGCAACCGAGGTGAGGGTGA CAGTGCTGAGGCAGGCAGACAGCCAGGTGACCGAGGTGTGCGCAGCAACATATATGATGGG CAACGAGCTGACCTTTCTGGACGATTCCATCTGTACCGGCACATCTAGCGGCAACCAAGTG AATCTGACCATCCAGGGCCTGAGAGCTATGGACACAGGCCTGTACATCTGTAAGGTGGAGC TGATGTATCCCCCTCCATACTATCTGGGCATCGGCAACGGCACACAAATCTACGTGATCGA TCCAGAGCCTTGCCCAGGAGGAGGAGGCTCCTCTGGAGGAGGAGGCTCCTCTTCTGAGGAT CTGTACTTTCAGAGCAGCCCAGGCCAGGGCACCCAGAGCGAGAACAGCTGTACACACTTCC CCGGCAACCTGCCTAATATGCTGCGGGACCTGAGAGATGCCTTTTCCAGGGTGAAGACCTT CTTTCAGATGAAGGACCAGCTGGATAACCTGCTGCTGAAGGAGTCCCTGCTGGAGGACTTC AAGGGCTACCTGGGCTGCCAGGCCCTGTCTGAGATGATCCAGTTTTATCTGGAGGAAGTGA TGCCACAGGCCGAGAATCAGGACCCCGACATCAAGGCCCACGTGAACTCTCTGGGCGAGAA TCTGAAGACACTGAGGCTGAGGCTGCGGAGATGCCACCGGTTCCTGCCCTGTGAGAACAAG TCTAAGGCCGTGGAGCAGGTGAAGAACGCCTTTAATAAGCTGCAGGAGAAGGGCATCTATA AGGCCATGAGCGAGTTCGACATCTTCATCAATTACATTGAAGCCTACATGACTATGAAGAT TAGAAACGGCAGCCACCATCACCATCACCATTAA (GST-CTLA4-IL10-6xHis construct, SEQ ID NO: 2).
[0174] The protein sequence of GST-CTLA4-IL10-6xHis is set forth in SEQ ID NO: 1 below:
[0175] MSPILGYWKIKGLVQP TRLLLEYLEEKYEEHL YERDEGDKWRNKKFELGLEFPNLP YYIDG D VKL TQSMA I IR YIADKHNML GGCPKERAEI SMLEGA VLD IR YGVSR I A YSKDFE TLKVDF LSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFML YDALDVVL YMDPMCLDAFPKLVCFKKRI EA IPQIDKYLKSSKYIA WPLQGWQA TFGGGDHPPKS DLEVLFQGPL G S HVAQP AWLAS SRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQV NLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPGGGGSSGGGGSSSED
[0176] ■LYFQSSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDF KGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENK SKAVEQVKNAFNKLQEKGI YKAMSEFD IF INYIEAYMTMKIRNG S HHHHHH* (GST- CTLA4-IL10-6xHis, SEQ ID NO: 1).
[0177] In SEQ ID NO: 1, GST is in italics, the HRV 3C site is underlined, CTLA4 is in bold, the glycine- serine linker is in italics and underlined, the TEV cleavage site is in bold italics, IL10 is in bold and underlined, and the 6xHis tag is in bold and underlined italics.
[0178] Example 2. Evaluating the bacterial expression of GST-tagged bispecific CTLA4-IL10
[0179] The bacterial ability to express the CTLA4-IL10 under different conditions was evaluated. A construct harboring the gene encoding for the CTLA4-IL10-6xHis (Fig. 1A) was cloned into pGEX-6P-l containing a GST N-terminus tag and transformed into E. coli BL21. The expressed protein translates into a 61 kDa protein composed of (from N- to C-terminus) GST, an HRV 3C cleavage site, CTLA4, a glycine- serine linker (GGGGSSGGGGSS, SEQ ID NO: 8), a TEV-protease linker cleavage site, IL10 and 6xHis-tag (SEQ ID NOs: 1 and 2, showing the protein sequence and the DNA sequence encoding the same, respectively). To test protein expression, bacterial cultures were grown in LB medium supplemented with 100 pg / mL ampicillin at 37 °C with constant shaking at 200 RPM until reaching OD6oo=0.8. Upon reaching the desired OD, protein expression was induced with 1 mM IPTG under three different conditions: 37 °C for 4 h, 25°C overnight, or 15°C overnight, after which cells were harvested by centrifugation at 4,500 xg for 45 min at 4 °C. Expression was evaluated by SDS-PAGE analysis of soluble and insoluble fractions of the culture broth. The results are summarized in Fig. IB.
[0180] Under all tested conditions, only a faint band was observed in the soluble fraction, whereas the majority of the recombinant protein was detected in the insoluble pellet, indicating predominant localization to bacterial inclusion bodies. Schematic representations of the multi-component fusion protein with and without the GST tag are shown in Fig. 1C.
[0181] Regardless of temperature, most of the protein was obtained within the inclusion bodies. Therefore, 25°C was chosen as the induction temperature for subsequent experiments. The protein expression protocol used was therefore as follows:The bispecific protein was overexpressed in E. coli strain BL21. Bacteria were grown in LB medium with 100 pg / mL of ampicillin at 37 °C at constant shaking. Protein expression was induced at an optical density (OD600) of 0.8 by the addition of 1 mM isopropylβ-d-thiogalactoside (IPTG). Following induction, the culture was further grown for 16 h at 25°C. Cells were collected and pelleted by centrifugation at 4500 xg for 45 min at 4 °C, and pellets were frozen and stored at -20 °C.
[0182] Example 3. CTLA4-IL10 solubilization and purification
[0183] After lysis and sonication, the sup and pellet fractions were analyzed by SDS-PAGE (Fig. 2A). Following both operations, the CTL4-IL10 was found mainly in the non-soluble fraction (pellet, Fig. 2A lanes 2, 4)) of the inclusion bodies. To solubilize the protein, the pellet was resuspended in a denaturation buffer containing 6 M guanidine hydrochloride. Following overnight incubation, the solubilized solution was filtered via 0.22 pm membrane (Fig 2A, lane 5). The denaturated chimera protein was first purified via Ni-NTA column, thereby removing contaminants and enhancing refolding efficiency (Fig. 2B). Despite some protein not binding to the column, the majority of the protein was eluted by imidazole-containing buffer in the elution fraction (Fig. 2B).
[0184] Example 4. Refolding of GST-CTLA4-IL10-6xHis
[0185] Following denaturation and Ni-NTA purification, protein refolding was done by two-step dialysis against a refolding buffer containing 3M and 0M urea. The presence of arginine, cystine and cysteine in the refolding buffer supports the formation of disulfide bonds while solubilizing the protein. At the end of the refolding step, the protein was filtered via 0.22 pm membrane, and the clear solution was analyzed by SDS-PAGE and Western blot. Fig. 3A shows SDS-PAGE of the solution, revealing a clear CTLA4-IL10 band. To assess the structural integrity of the refolded fusion protein and confirm expression of its individual domains, Western blot was performed using four different polyclonal antibodies; aHis, aGST, aCTLA4 and alLlO (Figs. 3B-3E). All components of the fusion protein were identified, indicating the integrity of the target protein (Fig. 3B-3E). A lower molecular size band was also observed on both SDS-PAGE and Western blot analysis, which may reflect partial proteolysis of the fusion protein.
[0186] Example 5. Binding activity of GST-CTLA4-IL10-6xHis to CD80 and Fc-ILIOR Next, the ability of the bispecific protein to bind its two cognate receptors IL10R and CD80 was evaluated via ELISA experiments.The GST-tagged bispecific CTLA4-IL10 protein was incubated overnight in a 96 well-plate at 4 °C, and afterward, it was washed 5 times with PBS-T 0.05%. 200 pL of blocking solution (5% skim milk in PBS-T 0.05%) was added and the plate was incubated for 5 h at RT to prevent non-specific binding. After incubation, the plate was washed 5 times with PBS-T 0.05% and 0.2 pg CD80 (His & AVI tag biotinylated, SinoBiological) or Fc-IL10R (R& D systems, USA) was added to relevant wells at a final volume of 100 pL. Next, the plate was incubated at 4 °C ON. Following 5 washes with PBS-T 0.05%, blocking for 2 h and additional washes, 100 pL of Fc-HRP conjugated antibody or streptavidin-HRP (1 pL antibody diluted in 7 mL PBS) were added at a final volume of 100 pL to relevant wells and incubated at RT for 1 h. Washing steps were repeated, then 100 pL of TMB (SurModics) were added to each well and the plate was incubated at RT up to 1 h. After color development, 50 pL of 0.5 M H2SO4were added to each well to stop the enzymatic reaction. Plate absorbance was immediately measured using a plate reader (BioTek synergy H1) at 450 nm absorbance.
[0187] The binding activity of refolded GST-CTLA4-IL10-6xHis to its cognate receptors was determined by ELISA (Figs. 4A, 4C). In addition, to determine specificity, GST was used as a negative control (Figs. 4B, 4D). As seen in Fig. 4, specific binding was demonstrated between the chimera protein to CD80 (Fig. 4A) and Fc-ILIOR (Fig. 4C).
[0188] The binding capacity of the fusion protein was further evaluated by sandwich ELISA. A schematic illustration of the assay is shown in Fig. 5B. To this end, a 96-well plate was coated with Fc-ILIOR. Following incubation with GST-CTLA4-IL10-6xHis or CTLA4 (as GST-CTLA4-6xHis) and extensive washing, the complex was incubated with biotin-labeled CD80. Streptavidin-conjugated HRP was used to assess the binding. The results are presented in Fig. 5A. As can be seen, GST-CTLA4-IL10-6xHis, but not GST-CTLA4-6xHis, selectively bound both receptors simultaneously. This shows that the fusion protein retains the functionality of both CTLA4 and IL 10.
[0189] To quantify the binding affinity of the bacterially produced CTLA4-IL10 fusion protein to its cognate receptors, biolayer interferometry (BLI) was performed using an Octet® RED96 system (Figs.5C-5F). Streptavidin biosensors were loaded with biotinylated IL10R (Fig. 5C-5D) or CD80 (Fig. 5E-5F) and kinetic interactions were measured by exposing the biosensors to the refolded CTLA4-IL10 protein as analyte at concentrations ranging from 0.01 to 2 pM. GST alone was included as a negative-control analyte to assessnonspecific interactions. Association and dissociation were monitored for 500s and 600s, respectively, enabling estimation of Konand Koffvalues (Table 2). Sensorgrams were globally fitted to a 1:1 binding model. The fusion protein bound specifically to both targets, yielding equilibrium dissociation constants (KD) of 155.3 nM for CD80 and 45.7 nM for IL10R.
[0190] Table 2. Kinetic binding parameters for bacterially produced CTLA-4-IL10 interacting with immobilized CD80 or IL-10R measured by BLI
[0191]
[0192] Values are mean ± SD from three independent experiments. KD calculated as Koff / Kon
[0193] In summary, the studies described in Examples 1-5 demonstrate the expression of GST-CTLA4-IL10-6xHis as inclusion bodies in BL21. Purified refolded protein was obtained from inclusion bodies using appropriate solubilization, purification and refolding procedures with 66% purity and a yield of 10 mg / L. GST-CTLA4-IL10-6xHis demonstrated binding to both CD80 and IL10R simultaneously, providing evidence that the refolded protein is functionally active. The process makes it possible to generate large quantities of a recombinant chimera protein beneficial for application as an immunosuppressive treatment.
[0194] Example 6. Vector construction for mammalian expression
[0195] Mammalian expression vectors encoding the following fusion proteins were constructed. The fusion proteins contained open reading frames (ORF) encoding CTLA4 and IL10 in various orders and copy numbers as specified below. Additional elements included were a secretion signal (SS), an IgG Fc domain (Fc), a hemagglutinin (HA) tag, a linker comprising the TEV cleavage site ENLYFQG (SEQ ID NO: 13, TEV) (more specifically - a glycine- serine linker (G / S linker) followed by the TEV cleavage site), and a 6xHis tag (HIS).Protein vl: Fc-CTLA4-G / S linker-TEV-ILlO-HA-HIS
[0196] This fusion protein contained (from N- to C-terminus): a secretion signal, Fc, CTLA4, a glycine- serine linker, a TEV cleavage site, a single copy of IL10 (IL10 monomer), HA tag and HIS tag, as set forth in SEQ ID NO: 3, as follows:
[0197] MGNSCIILFLVATATGVHSGPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLS PIVTCVVVD VSEDDPD VQI SWFVNNVEVHTAQ TQ THRED YNS TLR VVSALPIQHQD WMSGK EFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIY VEWT GKTFLNYKNTFPVLDSDGS YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTK S F S RT P GKHVAQP AWIAS SRGI ASFVCE YASP GKATEVRVTVLRQAD SQVTEVCAAT YMM GNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVI DPEPCPGGGGSSGGGGSSSENLYFQGSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKT FFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGE NLKTLRLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMK IRNGSYPYDVPDYAHHHHHH (Fc-CTLA4-G / S linker-TEV-ILlO-HA-HIS, SEQ ID NO: 3).
[0198] The DNA sequence encoding protein vl is set forth in SEQ ID NO: 42.
[0199] Protein v2: IL10- G / S linker-TEV-CTLA4-Fc-HA-HIS
[0200] This fusion protein contained (from N- to C-terminus): a secretion signal, a single copy of IL10 (IL10 monomer), a glycine- serine linker, a TEV cleavage site, CTLA4, Fc, HA tag and HIS tag, as set forth in SEQ ID NO: 4, as follows:
[0201] MGWS C 11 LF L VAT AT GVH S GP SPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMK DQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTL RLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGG GGSSGGGGSSSENL YFQGHVAQP AWLAS SRGI ASFVCE YASP GKATEVRVTVLRQAD SQV TEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLG
[0202] 1GNGTQ1YV1DPEPCPDSDGGGSRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMIS LSPIVTCVVVD VSEDDPD VQI SWFVNNVEVHTAQTQ THRED YNS TLR VVSALPIQHQD WMS GKEFKCKVNNKDLPAPIER TISKPKGSVRAPQVYVLPPPEEEMTKKQVTL TCMVTDFMPED I YVEWTNNGKTELNYKNTEP VLDSDGS YFMY SKLRVEKKNWVERNS Y S C S VVHEGLHNHHT TKSFSRTPGKGSYPYDVPDYAHHHHHH (IL10-G / S linker-TEV-CTLA4-Fc-HA-HIS, SEQ ID NO: 4).
[0203] The DNA sequence encoding protein v2 is set forth in SEQ ID NO: 41.
[0204] Protein v3: IL10x2- G / S linker-TEV-CTLA4-Fc-HA-HIS
[0205] This fusion protein contained (from N- to C-terminus): a secretion signal, two copies of IL10 separated by a G / S linker (IL10 dimer), a glycine- serine linker, a TEV cleavage site, CTLA4, Fc, HA tag and HIS tag, as set forth in SEQ ID NO: 5, as follows:
[0206] MGWS C 11 LF L VAT AT GVH S GP SPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMK DQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTL RLRLRRCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGG GSGGGSPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESLLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRRCHRFLPCENK SKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRNGGGGSSGGGGSSSENLYF QGHVAQPAWLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTF LDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCP DSDGGGSRGP T I KP CPP CKCPAPNLLGGP S VFIFPPKIKD VLMI SLSPIVTC VVVD VSEDD PD VQISWFVNNVEVHTAQTQ THRED YNS TLRVVSALP IQHQD WMSGKEFKCKVNNKDLPAP IERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYK NTE’PVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKGSYPYD VPDYAHHHHHH (IL10x2- G / S linker-TEV-CTLA4-Fc-HA-HIS, SEQ ID NO: 5).
[0207] The DNA sequence encoding protein v3 is set forth in SEQ ID NO: 40.
[0208] In SEQ ID NOs: 3-5, CTLA4 is in bold, glycine- serine linkers are in italics and underlined, the TEV cleavage site is in bold italics, IL10 is in bold and underlined, the 6xHis tag is in bold and underlined italics, and the Fc domain is in italics.
[0209] The constructs encoding these fusion proteins were cloned into the expression vector pcDNA3 and expressed in a mammalian expression system, namely Chinese Hamster Ovary (CHO-S) cells. Cells were maintained at 37°C in a humidified atmosphere containing 8% CO2 on an orbital shaker. Plasmid transfection was performed by mixing DNA with the transfection reagent at an optimal ratio and adding the complex to the culture, followed by the addition of the media feed supplement 24 hours post-transfection. For purification, the cell mixture was loaded onto AmMag™ Protein A magnetic beads. The beads were washed twice with PBS (pH 7.2) and once with ddH2O. The protein was then eluted with 0.1 M glycine-HCl (pH 2.5-3.0), followed by immediate buffer exchange to a sodium acetate buffer, 0.2 M L-arginine, pH 5.5. The fusion proteins were evaluated as described in Examples 7-11 below.
[0210] Example 7. Expression and evaluation of Fc-CTLA4-G / S linker- TEV-IL10-HA-HIS
[0211] Protein vl was first evaluated by SDS-PAGE, under reducing (R) and non-reducing (NR) conditions. The results are presented in Fig. 6A, in which lane M indicates a protein marker (BioRad Cat. No. 1610374S). As can be seen, the reduced protein shows a single band with the correct molecular size of the glycosylated protein, indicating its successful expression and purification. The non-reduced protein sample shows multiple higher molecular weight bands, consistent with the formation of protein oligomers. Without wishing to be bound by a specific theory or mechanism of action, oligomerization may represent native dimerization of IL10 and CTLA4.Next, binding assays were performed as follows. First, coating was made with the chimeric protein or a corresponding receptor (CD80 in Fig. 6B, Fc-ILIOR in Fig. 6C), diluted to 2 pg / well at a final volume of 100 pL. The plate was incubated ON at 4 °C, and afterward, it was washed 5 times with PBS-T 0.05%. 300 pL of blocking solution (5% skim milk in PBS-T 0.05%) was added and the plate was incubated for 5 h at RT to prevent nonspecific binding. After incubation, the plate was washed 5 times with PBS-T 0.05% and 0.2 pg / well CD80, Fc-ILIOR or 0.5 pg / well chimeric protein was added to relevant wells at a final volume of 100 pL, as indicated in Figs. 6B-6C. Next, the plate was incubated at 4 °C ON. Following 5 washes with PBS-T 0.05%, blocking for 2 h and additional washes, 100 pL of streptavidin-HRP or anti-6xHis-HRP (1 pL antibody diluted in 10 mL PBS) were added at a final volume of 100 pL to relevant wells and incubated at RT for 45 min. Washing steps were repeated, then 100 pL of TMB were added to each well and the plate was incubated at RT up to 1 h. After color development, 50 pL of 0.5 M H2SO4were added to each well to stop the enzymatic reaction. Plate absorbance was immediately measured using a plate reader at 450 nm absorbance. The results are presented in Fig.6B (CD80) or Fig.6C (Fc-ILIOR).
[0212] As can be seen from Figs. 6B-6C, the fusion protein was able to bind both cognate receptors in a specific manner.
[0213] Example 8. Expression and evaluation of IL10-CTLA4-Fc-HA-HIS
[0214] Protein v2 was evaluated by SGS-PAGE and binding assay essentially as described in Example 7. The results are presented in Figs. 7A and 7B-7C, respectively.
[0215] As can be seen from Fig.7A, the reduced protein shows a single band with the correct molecular size of the glycosylated protein, indicating its successful expression and purification. The non-reduced protein sample shows the formation of high molecular weight bands consistent with the formation of protein oligomers. Without wishing to be bound by a specific theory or mechanism of action, oligomerization may represent native dimerization of IL10 and CTLA4. As can be seen from Figs. 7B-7C, the fusion protein was able to bind both cognate receptors in a specific manner.
[0216] Example 9. Expression and evaluation of IL10x2-CTLA4-Fc-HA-HIS Protein v3 was evaluated by SGS-PAGE and binding assay essentially as described in Example 7. The results are presented in Figs. 8A and 8B-8C, respectively.As can be seen from Fig.8A, the reduced protein shows a single band with the correct molecular size of the glycosylated protein, indicating its successful expression and purification. The non-reduced protein sample shows high molecular weight bands consistent with the formation of protein oligomers. Importantly, a higher ratio of a protein with the size of a single homodimer (-160 kDa) is observed in the NR lane of Fig. 8A relative to Figs.
[0217] 6A and 7A, indicating improved assembly of the IL10x2-CTLA4-Fc-HA-HIS protein compared to the variants containing a single copy of IL 10. Accordingly, and without wishing to be bound by a specific theory or mechanism of action, the use of a construct comprising two IL-10-encoding ORFs (IL10 dimer) imparts intra-dimerization in the resulting fusion protein, leading to a more homogeneous protein product. Structural models of the tandem IL- 10 construct are shown with the C-terminal Fc domain (Fig. 8D) and without Fc (Fig.
[0218] 8E).
[0219] As can be seen from Figs. 8B-8C, the fusion protein was able to bind both cognate receptors in a specific manner.
[0220] To quantify the binding kinetics and steady-state affinity of the IL10x2-CTLA4-Fc- HA-HIS fusion protein produced by mammalian in cells for its cognate receptors, BLI was performed using the same experimental conditions as for the bacterial protein. The results are shown in Figs. 8F-8G. Biotinylated receptors were immobilized on streptavidin biosensors and incubated with the mammalian cell-produced fusion protein at concentrations ranging from 0.01 to 2 pM in PBS supplemented with 0.02% Tween-20. Association and dissociation were monitored for 500s and 600s, respectively, enabling estimation of Konand Koffvalues (Table 3), and sensorgrams were globally fitted to a 1:1 binding model. The mammalian cell-produced fusion protein bound to CD80 with an apparent equilibrium dissociation constant (KD) of 462.8 ± 11.98 nM, and exhibited extremely tight binding to IL10R with a KD below the detection limit (<1 pM).
[0221] Table 3. Kinetic binding parameters for the mammalian cells-produced protein IL10x2-CTLA4-Fc-HA-HIS interacting with immobilized CD80 or IL10R measured by BLI
[0222]
[0223]
[0224] Values are mean +SD from three independent experiments. KD is calculated as Koff / Kon. Example 10. Immunomodulation in cell cultures
[0225] Fusion proteins were evaluated functionally in cell culture models. To this end, RAW 264.7 macrophage cells were incubated with or without lipopolysaccharide (LPS) and different concentrations of the fusion protein (vl). The immunosuppressant dexamethasone (DEXA) and recombinant IL10 (R-IL10) were used as a positive control, and cells without any treatment were used to assess the basal state and indicated as control. The fusion protein, R-IL10 or dexamethasone were added and incubation was for 20 minutes, following with LPS (lOOng / ml) for 4 hours at 37°C. Tumor necrosis factor alpha (TNFα) levels were evaluated by ELISA according to the manufacturer's instructions. The results are presented in Fig. 9.
[0226] As can be seen in Fig. 9, the fusion protein was capable of significantly inhibiting TNFα secretion from LPS-activated macrophages, in a dose-dependent manner and had no off-target effect of the naive inactivated cells in the absence of LPS. This effect was similar and comparable to the obtained inhibitory effect of DEXA and R-IL10. Thus, the fusion protein in accordance with the invention exhibited a potent immunosuppressive activity at least comparable to that of dexamethasone and R-IL10, as evident from Fig.9.
[0227] Example 11. Effect on IFNy secretion from activated T-cells
[0228] The ability of virus-specific T cells (VSTs) to secrete IFNy in response to the adenovirus-derived Hexon antigen in the absence / presence of IL10, CTLA4, or an IL10-CTLA4 fusion protein (v3) was evaluated.
[0229] Generation of virus-specific T-cells
[0230] Fresh peripheral blood mononuclear cells (PBMCs) from a healthy donor were isolated from whole blood by density-gradient centrifugation using Lymphoprep™ Ficoll (Serumwerk Bemburg AG). PBMCs were seeded in 24-well plates (3×106cells per well) (Greiner) in virus-specific T cell (VST) medium composed of a 1:1 mixture of AIM V (Gibco) and RPMI 1640 (Sartorius), supplemented with 1% L-glutamine (Sartorius), 1%penicillin-streptomycin (Sartorius), and 10% human serum (Access Biologicals). Cells were stimulated in vitro with an adenovirus Hexon peptide library (Miltenyi Biotec) at a final concentration of 200 ng / mL and 1 ng / mL for 2 hours, followed by incubation at 37°C in 5% CO2. After 2 hours, fresh medium was added, and cells were cultured for an additional 3 days under the same conditions. Every 3 days thereafter, cells were expanded into larger culture vessels with fresh VST medium supplemented with interleukin-2 (IL2; 300 lU / mL; Clinigen) and maintained at 37°C in 5% CO2. Cells were expanded for 10-12 days for VST enrichment before cryopreservation.
[0231] Co-culture assay for quantifying IFNy levels
[0232] PBMCs from the same donor were thawed and seeded at 7×105cells per well in 96-well plates (Greiner) containing VST medium. Cells were incubated for 2 hours at 37 °C with 5% CO2 to allow adherence. Non-adherent cells were removed by washing, leaving a population enriched by antigen-presenting cells (APCs; ±10% of total cells). APCs were loaded with the Hexon peptide library (Miltenyi Biotec) at either 200 ng / mL or 1 ng / mL for 2 hours at 37 °C with 5% CO2. Thirty minutes before co-culture, VSTs were seeded at 1×105cells per well in a separate 96- well plate with VST medium. The plate was centrifuged at 1,300 rpm for 5 minutes; the supernatant was removed, VSTs were resuspended in medium containing IL10, CTLA4 (recombinant, commercially available, or the CTLA4-IL10 fusion protein (v3) at 200 nM, and incubated for 30 minutes at 37°C. The VSTs were then added to the antigen-loaded APCs to initiate co-culture. The co-cultures were incubated for 18 hours at 37 °C with 5% CO2. VSTs treated with PBS served as a control. After incubation, culture supernatants were collected and analyzed for interferon-y (IFN-y) secretion by ELISA according to the manufacturer's protocol (BioLegend).
[0233] The results are summarized in Figs. 10A-10B. The results demonstrate that VSTs that were exposed to the Hexon antigen at 200 ng / ml (Fig. 10A) and 1 ng / ml (Fig. 10B) secreted high levels of IFNy as compared to the no antigen group in a dose-dependent manner. IL10 and CTLA4 individually inhibited activation of the VSTs, as evident by the significantly lower levels of IFNy levels compared to activated cells not treated with the proteins, confirming their immunomodulatory functions. Importantly, the IL10-CTLA4 fusion protein also effectively inhibited VST activation, and was even better than each component alone under high antigen conditions (200 ng / ml).
[0234] In summary, the studies described in Examples 6-11 demonstrate the expression of several fusion proteins in a mammalian expression system, with high yield and purity.Remarkably, the CHO system delivered a superior yield of approximately 39 mg / L. The fusion proteins were capable of selectively binding to CD80 and IL10R simultaneously. Further, the tested fusion proteins were determined to inhibit the secretion of pro-inflammatory cytokines during both homeostasis and inflammatory conditions. The observed immunosuppressor activity was at as potent as that of dexamethasone, a glucocorticoid anti-inflammatory and immunosuppressive drug.
[0235] Glucocorticoids belong to the strongest class of drugs available for reducing inflammation in the body, and are thus used for the treatment of autoimmune diseases and other severe and life-threatening conditions. However, glucocorticoids are associated with prominent adverse effects, limiting their use to those cases in which their benefit is likely to exceed their risk. The ability to limit the immunosuppressor activity to selected target cells expressing both IL10R and CD80 / CD86, as demonstrated herein for the newly constructed fusion proteins, provides for improved therapeutic modalities characterized by enhanced efficacy and improved safety and tolerability.
[0236] Example 12 - Inhibition of T-cell activation by CTLA4-IL10 chimeric protein The effect of a CTLA4-IL10 chimeric protein (v3) on T-cell activation was evaluated using a Raji-Jurkat NF AT luciferase reporter assay.
[0237] Raji cells expressing CD80 were pre-incubated with the chimeric protein (10 pM) for 30 minutes and then co-cultured with Jurkat T cells expressing CD28 and an NFAT-driven luciferase reporter. Following approximately 4.5 hours of co-culture, luciferase activity was measured.
[0238] Co-culture of Raji and Jurkat cells resulted in induction of NFAT-driven luciferase activity. Treatment with the chimeric protein significantly reduced luciferase activity relative to control (Fig. 11). Remarkably, the chimeric protein exhibited far greater inhibition of luciferase activity compared to CTLA4 alone (which showed no inhibition) and IL 10 alone under the same conditions. Data are presented as mean ± standard deviation and were analyzed using one-way ANOVA.
[0239] Example 13 - Generation and characterization of IL10 variants with improved IL10R binding
[0240] A library of IL 10 variants was generated to identify modified IL 10 polypeptides exhibiting altered binding affinity to the IL 10 receptor (IL10R).Mutagenesis and library construction
[0241] The gene encoding human IL10 was subjected to random mutagenesis using error-prone PCR under conditions introducing nucleotide substitutions throughout the coding sequence. The resulting amplified products were cloned into the pGEX expression vector and transformed into E. coli DH5a cells, generating a library of approximately 1.5 x 105independent transformants.
[0242] The mutant library was screened for IL10R binding activity.
[0243] Screening for IL1 OR binding
[0244] Screening was performed using an ELISA-based assay. Briefly:
[0245] • IL10 variants were expressed as GST-fusion proteins;
[0246] • Individual colonies were cultured in 96-deep-well plates, expression was induced with IPTG, and bacterial lysates were prepared and captured using anti- GST-coated plates;
[0247] • Binding to IL10R was detected using biotinylated IL10R followed by strep tavidin-HRP;
[0248] • Variants exhibiting altered binding relative to wild-type IL 10 were identified based on absorbance at 450 nm.
[0249] Identification of functional variants
[0250] Selected variants that demonstrated improved binding to IL-10R were re-tested, and those demonstrating confirmed enhancement relative to the wild type were sequenced to determine their mutations. Selected variants with confirmed binding enhancement were expressed in E. coli BL21 as GST-fusion proteins and purified using the refolding protocol described above for the CTLA4-IL10 fusion protein, followed by dialysis into PBS and quantification by Bradford assay. The purified IL10 variants were then subjected to a more detailed analysis of their IL10R binding, which included sandwich ELISA and also assessment of quantitative binding kinetics using biolayer interferometry (BLI). For sandwich ELISA, plates were coated with anti-GST antibody to capture the IL10 proteins, then incubated with ILIOR-Fc chimera followed by anti-human-HRP detection. Serial dilutions (3 pM starting concentration with 4-fold dilutions) enabled comparison of binding affinities. Improved binding signals compared to wild-type IL10 at equivalent protein concentrations was considered as enhanced IL10R affinity.
[0251] For BLI analysis, biotinylated IL10R was immobilized on streptavidin biosensors and incubated with serial dilutions of IL10 wild-type or variants (0.005-0.75 pM) in PBScontaining 0.02% Tween-20 and 0.1% BSA. Association and dissociation phases were monitored for 500s and 600s, respectively. Sensorgrams were fitted to a 1:1 binding model to extract kinetic parameters. Selected variants with improved binding to IL10R are summarized in Table 4.
[0252] Table 4. Selected variants with improved binding to IL10R
[0253]
[0254] In variant P1G9 there is also a silent mutation at Glu75 and in variant P2F5 there is also a silent mutation at His90.
[0255] The values represent relative signal obtained in the ELISA assay compared to wildtype IL10 under identical conditions.
[0256] *The positions of the substitutions are with respect to the sequence of the mature wild-type IL10 (namely, the mature form produced after cleavage of the native signal peptide) as set forth in SEQ ID NO: 39.
[0257] Amino acid sequences ofIL-10 variants
[0258] The amino acid sequence of wild-type IL10 used as reference is as follows (positions that are mutated in the variants are in bold and underlined):
[0259] SPGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKES LLEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLR RCHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
[0260] (wtILlO, SEQ ID NO: 39).
[0261] The amino acid sequences of IL- 10 variants identified in the screen are as follows (mutated positions are in bold and underlined; the variant sequences are provided without theN-terminal serine residue of the mature IL- 10 protein, as this residue was not included when the variants were cloned into the GST-containing expression vector):
[0262] Variant Pl G7:
[0263] PGQGTQSENSCTHFPCNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPEIKAHVNSLGENLKTLRLRLRRC HRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN (P1G7 IL10 variant, SEQ ID NO: 24).
[0264] Variant Pl G9:
[0265] PGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQKKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRR CHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
[0266] (P1G9 IL10 variant, SEQ ID NO: 23).
[0267] Variant P2C4:
[0268] PGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKPFFQMKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVNSLGENLKTLRLRLRR CHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
[0269] (P2C4 IL10 variant, SEQ ID NO: 26).
[0270] Variant P2F5:
[0271] PGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAENQDPDIKAHVDSLGENLKTLRLRLRR CHRSLPCENKSKAVEQVKNEFNMLQEKGIYKAMSEFDIFINYIEAYMTMKIRN
[0272] (P2F5 IL10 variant, SEQ ID NO: 25).
[0273] Variant P5D7:
[0274] PGQGTQSENSCTHFPGNLPNMLRDLRDAFSRVKTFFQMKDQLDNLLLKESL LEDFKGYLGCQALSEMIQFYLEEVMPQAGNQDPDIKAHVNSLGENLKTLRLRLRR CHRFLPCENKSKAVEQVKNAFNKLQEKGIYKAMSEFDIFINYIEACMTMKIRN
[0275] (P5D7 IL10 variant, SEQ ID NO: 27).
[0276] For recombinant production of the IL10 variants, the proteins were designed to include a 6*His tag at their C-terminus (SEQ ID NOs: 18-22, corresponding DNA sequences are set forth in SEQ ID NOs: 29-33). A wild-type IL10 containing a His tag for recombinantproduction was also constructed, as a control construct (SEQ ID NO: 16, a corresponding DNA sequence is set forth in SEQ ID NO: 28).
[0277] Nucleic acid sequences encoding the IL10 variant including a C-terminal His tag are set forth in SEQ ID NOs: 29-33.
[0278] These results demonstrate IL 10 variants comprising one or more amino acid substitutions that exhibit improved binding to IL10R. Such variants are suitable for incorporation into chimeric CTLA4-IL10 proteins, to modulate immunoregulatory activity.
[0279] Functional characterization
[0280] To validate biological function, IL10 variants were tested in LPS- stimulated RAW 264.7 murine macrophages. Specifically, RAW 264.7 macrophage cells were incubated with or without lipopolysaccharide (LPS) and different concentrations of the proteins. The immunosuppressant dexamethasone (DEXA) was used as a positive control (PC), and recombinant IL10 (either mouse or human) were used as controls as well. Cells without any treatment were used to assess the basal state and indicated as NC. The proteins or dexamethasone were added for 20 minutes, following with LPS (lOOng / ml) for 4 hours at 37°C. Tumor necrosis factor alpha (TNFα) levels were evaluated by ELISA according to the manufacturer's instructions. Exemplary results (P1G9 variant) are shown in Fig. 12. As can be seen in Fig. 12, the WT IL 10 and mutant IL 10 proteins were capable of significantly inhibiting TNFα secretion from LPS-activated macrophages., Notably, the mutant proteinwas more potent compared to the WT and showed highly efficient inhibition already at the low dose of 1 ng / ml.
[0281] Example 14 - Evaluation of CTLA4-IL10 fusion protein in oxazolone-induced DTH
[0282] 1. Study objective
[0283] To evaluate the in vivo anti-inflammatory efficacy of CTLA4-IL10 bispecific fusion proteins in a mouse model of Delayed Type Hypersensitivity (DTH).
[0284] 2. Animals
[0285] • Strain: Female BALB / c mice.
[0286] • Age: 7 weeks old at the start of the study.
[0287] • Acclimation: 5-7 days prior to Day 0.
[0288] 3. Dosing and administration strategy
[0289] All treatments are administered via intraperitoneal (i.p.) route. Because the test articles have vastly different in vivo half-lives (e.g., free IL10 is cleared in minutes, whereas Fc-fusion proteins last for days), treatments follow one of two schedules from Day 0 to Day 6:
[0290] • Schedule A (Twice Daily / BID): designed to maintain therapeutic levels of short-acting compounds and to properly control for the stress of frequent i.p. injections.
[0291] • Schedule B (Every Other Day / Q. O. D): designed for the extended pharmacokinetics of Fc-fusion proteins, administered on Days 0, 2, 4, and 6.
[0292] 4. Experimental groups (n = 10 mice / group )
[0293] 1. Naive (Negative Control): No DTH induction; no treatment.
[0294] 2. Vehicle (Disease Control): Oxazolone + PBS.
[0295] 3. Positive Control: Oxazolone + Dexamethasone.
[0296] 4. CTLA4 Monotherapy: Oxazolone + CTLA4-Fc.
[0297] 5. IL 10 Monotherapy: Oxazolone + Recombinant IL- 10.
[0298] 6. Unconjugated Mixture: Oxazolone + CTLA4-Fc + rIL-10.
[0299] 7. CTLA4-IL10 Fusion Protein: Oxazolone + CTLA4-IL10-Fc.
[0300] 5. Experimental Timeline and Procedures
[0301] Day 0: Sensitization phase
[0302] o The ventral abdomen of the mice is shaved.o The DTH model is induced by topically applying 200 pL of a 2.0% (w / v) Oxazolone solution (dissolved in acetone and olive oil) to the shaven abdomen.
[0303] o The i.p. dosing regimens for all treatment groups is initiated.
[0304] • Days 1 to 5: Treatment and monitoring
[0305] o Treatments are administered according to the schedules defined above. o Body weight is monitored and recorded daily to assess for systemic toxicity, treatment-related weight changes, or stress from frequent i.p. injections.
[0306] • Day 6: Baseline measurement & challenge phase
[0307] oThe baseline ear thickness of all mice is measured using a digital micrometer.
[0308] o The challenge phase is induced by topically applying 50 pL of a 0.5% or 1% (w / v) Oxazolone solution to one ear.
[0309] • Day 7 or later: termination and evaluation (24 hours post-challenge)
[0310] o Ear thickness is re-measured using the digital micrometer to determine the magnitude of the DTH response.
[0311] o Final body weight changes are calculated.
[0312] o The mice are Euthanized.
[0313] o The challenged ears are collected and fixed in formalin for histopathological evaluation.
[0314] Evaluated parameters & endpoints
[0315] • Ear swelling (primary efficacy endpoint): calculated as the difference in ear thickness between Day 6 (pre-challenge) and Day 7 (post-challenge). Successful therapy yields a statistically significant reduction in swelling compared to the vehicle group.
[0316] • Body weight change (safety / systemic endpoint): evaluated as a percentage change from Day 0.
[0317] • Histopathology: ears are sectioned, H& E stained, and evaluated under 4X magnification for:
[0318] o Epidermis thickness and integrity (necrosis).
[0319] o Presence of diffuse edema (pale areas).
[0320] o Severity of moderate-to-severe inflammatory cellular infiltrates.The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.
Claims
CLAIMS1. A chimeric protein comprising a Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) polypeptide covalently linked by a linker to an Interleukin-10 (IL10) polypeptide.
2. The chimeric protein of claim 1, wherein the CTLA4 polypeptide is derived from a human CTLA4 and comprises at least the ectodomain of the human CTLA4.
3. The chimeric protein of claim 2, wherein the CTLA4 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 15 or an amino acid sequence having at least 95% sequence identity thereto.
4. The chimeric protein of any one of the preceding claims, wherein the CTLA4 polypeptide consists essentially of one or more CTLA4 ectodomains.
5. The chimeric protein of any one of claims 1-4, wherein the CTLA4 polypeptide consists essentially of a single CTLA4 ectodomain.
6. The chimeric protein of any one of claims 4-5, wherein the CTLA4 ectodomain comprises the amino acid sequence set forth as SEQ ID NO: 15 or an amino acid sequence having at least 95% sequence identity thereto.
7. The chimeric protein of any one of the preceding claims, wherein the IL10 polypeptide is derived from a human IL10.
8. The chimeric protein of claim 7, wherein the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 17 or an amino acid sequence having at least 95% sequence identity thereto.
9. The chimeric protein of claim 7, wherein the IL10 polypeptide comprises one or more amino acid substitutions relative to wild-type IL10.
10. The chimeric protein of claim 9, wherein the wild-type IL10 has the amino acid sequence set forth as SEQ ID NO: 39, and wherein the IL10 polypeptide comprises one or more substitutions at positions selected from 17, 35, 39, 81, 86, 92, 111, 127, 130, and 153 of SEQ ID NO: 39.
11. The chimeric protein of claim 10, wherein the one or more substitutions are independently selected from Glyl7Cys, Thr35Pro, Met39Lys, Glu81Gly, Asp86Glu, Asn92Asp, PhelllSer, Alal27Glu, Lysl30Met, and Tyrl53Cys.
12. The chimeric protein of claim 11, wherein the IL10 polypeptide comprises a combination of substitutions selected from:(a) Glyl7Cys and Asp86Glu;(b) Met39Lys;(c) Thr35Pro;(d) Asn92Asp, PhelllSer, Alal27Glu, and Lysl30Met; and(e) Glu81Gly and Tyrl53Cys.
13. The chimeric protein of any one of claims 9-12, wherein the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 23-27.
14. The chimeric protein of any one of the preceding claims, wherein the IL10 polypeptide consists essentially of an IL10 monomer.
15. The chimeric protein of any one of claims 1-13, wherein the IL10 polypeptide consists essentially of an IL10 dimer.
16. The chimeric protein of claim 15, wherein the IL10 polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 38 or an amino acid sequence having at least 95% sequence identity thereto.
17. The chimeric protein of any one of the preceding claims, wherein the CTLA4 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15, and the IL10 polypeptide comprises an amino acid sequence selected from SEQ ID NO: 17, SEQ ID NOs: 23-27, and SEQ ID NO: 38.
18. The chimeric protein of any one of the preceding claims, wherein the linker is a peptide linker of 10-20 amino acids in length.
19. The chimeric protein of any one of the preceding claims, wherein the linker is a flexible peptide linker.
20. The chimeric protein of claim 19, wherein the linker is a Gly-Ser linker.
21. The chimeric protein of any one of the preceding claims, further comprising at least one protein tag selected from the group consisting of: an affinity tag, a solubility tag, an expression tag and combinations thereof.
22. The chimeric protein of any one of the preceding claims, which is a chimeric protein precursor adapted for manufacture in a bacterial expression system.
23. The chimeric protein of claim 22, further comprising an N-terminal glutathione S-transferase (GST) tag and a C-terminal histidine tag.
24. The chimeric protein of claim 23, having the amino acid sequence as set forth in SEQ ID NO: 1.
25. The chimeric protein of any one of the preceding claims, which is a chimeric protein precursor adapted for manufacture in a mammalian expression system.
26. The chimeric protein of claim 25, further comprising a human IgG Fc domain, a hemagglutinin (HA) tag and a histidine tag.
27. The chimeric protein of claim 26, having the amino acid sequence as set forth in any one of SEQ ID NOs: 3-5.
28. The chimeric protein of any one of the preceding claims, which is devoid of solubility tags and expression tags.
29. A nucleic acid construct encoding the chimeric protein of any one of the preceding claims.
30. The nucleic acid construct of claim 29, having a nucleic acid sequence selected from SEQ ID NOs: 2, 40-42.
31. An expression vector comprising the construct of claim 29 or 30.
32. A host cell comprising the expression vector of claim 31.
33. A pharmaceutical composition comprising the chimeric protein of claim 28 or a nucleic acid construct encoding same, further comprising a pharmaceutically acceptable carrier, excipient or diluent.
34. The pharmaceutical composition of claim 33, for use as a medicament.
35. The pharmaceutical composition of claim 34, for use in treating or preventing an inflammatory or autoimmune disorder.
36. The pharmaceutical composition for use of claim 35, wherein the disorder is an autoimmune disorder selected from the group consisting of: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), celiac disease and type I diabetes.
37. The pharmaceutical composition for use of claim 35, wherein the disorder is a chronic inflammatory disorder, a gastrointestinal inflammatory disorder or an allergic disorder.
38. The pharmaceutical composition of claim 34, for use in reducing side effects associated with administration of an IL10 and / or CTLA4 therapy.
39. A method for immunomodulation, comprising contacting immune cells characterized by surface expression of IL10R and at least one of CD80 and CD86, with the pharmaceutical composition of claim 34.
40. The method of claim 39, wherein the contacting is performed in vivo.
41. The method of claim 39, wherein the contacting is performed ex vivo.
42. A method for treating or preventing an inflammatory or autoimmune disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 34.
43. The method of claim 42, wherein the disorder is an autoimmune disorder selected from the group consisting of: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), celiac disease and type I diabetes.
44. The method of claim 42, wherein the disorder is a chronic inflammatory disorder, a gastrointestinal inflammatory disorder or an allergic disorder.
45. A method for reducing side effects associated with administration of an IL10 and / or CTLA4 therapy in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 34.
